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Molecular and Mechanistic Anaiysis of HIV Nef
Abstract
The nef gene of HIV is required for complete viral pathogenicity. As an accessory gene with no 
known paradigm its principle function has been enigmatic. Nef is capable of a variety of in vitro 
effects including CD4 downregulation, MHC I down regulation, alteration of T cell signalling activity 
and enhancement of viral infectivity. The effect of Nef on host CD4 T cell signalling paths is 
intriguing as it is the earliest expressed HIV gene and because HIV replicates to high levels in 
activated host cells. An effect of Nef on T cell activation state could dictate host T cell fate tipping 
the balance between productive viral infection and post-integration latency. Although Nef can 
form in vitro interactions with a variety of T cell signalling proteins in vivo evidence for signalling 
path activation has been inconclusive mainly due to the limitations of the experimental systems 
used to address the question.
An in vivo role for Nef in alteration of T cell activation state should lead to gene expression 
changes in the host cell. Large scale gene expression profiling was used to monitor T cell gene 
expression after controlled expression of Nef using the tetracycline inducible system. Nef induces 
a widespread transcriptional program in T cells. Comparison of this profile with reference T ceil 
activation states reveals a strong identity to the gene expression profile of Jurkat activated by 
anti-CD3 cross-linking. Gene expression profiling was used to explore the mechanism by which 
Nef mediates this effect. After cyclosporin treatment the profiie was attenuated. A similar effect 
was observed after Nef expression in Jurkat T cells genetically deficient in ZAP-70 and 
functionally deficient in TCRÇ. Expression of a mutant defective in a functional SH3 binding 
domain had a stronger effect on attenuation of gene induction. Thus gene expression profiling 
demonstrates definitively Nef is capable of activating T cells at the transcriptional level and that 
this effect is initiated high in the T cell signalling path.
Within the Nef expression profile differential expression of multiple genes with the ability to affect 
virai replication was noted. In a few instances it was possible to demonstrate the Nef mediated 
changes in mRNA levels were functionally significant. Proteomic analysis of Nef effect on T cells 
was initiated. 2D gel analysis of T cell lysates after Nef expression demonstrated a differential 
regulation of proteins in T cell lysates. The mechanism by which Nef initiates T cell signalling was 
explored using a similar approach. The proteins interacting with Nef in lipid rafts were identified 
after immunoprécipitation of HA tagged Nef from this subcellular compartment. 2D gel analysis 
reveals the presence of Nef changes the content of lipid rafts and that Nef co-immunoprecipitates 
with several proteins in the raft fraction. The identity of these interactors obtained by peptide 
microsequencing should give insight into the molecular mechanism by which Nef induces a CD4 
T cell transcriptional programme.
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Chapter 1
1.1 Introduction
Acquired Immune Deficiency Syndrome (AIDS) was first described in 1982 after 
observation of illnesses experienced by clusters of patients in New York and San 
Francisco consisting of opportunistic infections and tumours in the context of a 
low CD4 count. Human Immunodeficiency Virus type 1 (HIV-1) was first isolated 
from the blood of AIDS patients in 1983-4 (Barre-Sinoussi et al., 1983, Popovic et 
al., 1984, Levy et al., 1984). Initially the infection appeared to be contained within 
a few high “risk groups” however within a few years it became clear the virus was 
spreading rapidly. Currently over 40 million people are infected with HIV-1 
throughout the world and the epidemic is increasing.
The origins of HIV infection in humans remain somewhat enigmatic. 
Mathematical modelling of viral diversification has been used to estimate when 
HIV became a human infection. This is possible as HIV possesses inherent 
variability due to lack of proof reading in the viral reverse transcriptase (Roberts 
et al., 1988) and as the virus replicates rapidly (Perelson et al., 1997). Viral 
diversification modelling has utilised sequence data and time of sampling to 
estimate the minimum amount of time HIV has been a human infection. It has 
been proposed that the main (M) group of HIV-1 strains currently infecting the 
human population began to diversify around 1930 (Korber et al., 2000, Korber et 
al., 2001). It has been postulated HIV spread to humans from a closely related 
primate species. In the case of HIV-2 (a retrovirus strain sharing 40-60% 
homology with HIV-1) there is a high degree of homology with SIV strains 
infecting sooty mangabeys (SIV sm) in the same part of West Africa (Gao et al., 
1992). The origin of HIV-1 is possibly from SIV infecting a chimpanzee species 
whose habitat overlaps with the central African area from where the M group of 
HIV-1 originated (Gao et al., 1999). The majority of people infected with HIV-2 
will not die of this virus in contrast to HIV-1 where an inevitable decline in CD4
in
count is observed. Lentiviral infection in natural hosts likewise largely results in 
little evidence of disease although persistent infection is present. Sooty 
mangabeys and African Green Monkeys infected with SIVsm or SIVagm appear 
healthy (Broussard et al., 2001, Kaur et al., 1998, Rey-Cuille et al., 1998). In 
addition many chimpanzees infected with HIV-1 remain immunologically intact 
over decades. An exception is that SIV strains can rapidly kill macaques (Daniel 
et al., 1987).
1.2 HIV enters human cells via CD4 and chemokine receptors
HIV infects CD4+ T-helper cells as well as other CD4 bearing cells such as 
macrophages and dendritic cells. The CD4 molecule was shown to be a high 
affinity receptor for the virus in 1984 (Dalgleish et al., 1984, Klatzmann et al., 
1984). In addition to CD4, coreceptors are required for HIV entry. Transfection of 
CD4 alone into many mammalian cell lines does not make them permissive for 
HIV infection. HIV coreceptors belong to the family of seven transmembrane 
spanning chemokine receptors. Several members of this family can function as 
coreceptors though at physiological levels of infection the main ones utilised are 
CXCR4 and CCR5. CXCR4 is the receptor for strains of HIV often found in late 
stage disease (syncytium inducing (81) or T cell tropic (Feng et al., 1996). Strains 
that establish primary infection are termed macrophage tropic or non-syncytium 
inducing (NSI). It was demonstrated that the chemokine receptor binding three 
HIV suppressing CC-chemokines (MIP-1a, MIP-ip and RANTES) was the major 
coreceptor for macrophage tropic HIV (Dragic et al., 1996, Deng et al., 1996). In 
vivo observations of HIV tropism were explained following these observations 
and the terms NSI/SI were superseded by defining the co-receptor usage (R5 or 
X4) for a particular isolate. Primary HIV infection generally requires CCR5 to 
become established. During the course of the infection viral tropism widens as a 
result of envelope V3 loop mutations. In late disease the infecting viral 
quasispecies changes tropism predominantly from CCR5 to CXCR4 and this is 
often coincident with a decline in CD4 cells (Connor et al., 1997). OCRS is largely
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expressed on memory T cells of the Th-1 type (Loetscher et al., 1998) and is 
induced on T cell activation. CXCR4 possesses a wider distribution particularly 
on naïve T-cells (BleuI et al., 1997). The parameters controlling this HIV tropism 
change during disease evolution are not known.
1.3 HIV depletes CD4 T cells
The hallmark of HIV disease is the decline in CD4 count that is coincident with 
susceptability to AIDS defining opportunistic infections and malignancies. The 
mechanism by which this occurs is not clear. Measurements of infected T cells in 
the circulation recorded low values that seemed at odds with the extent of 
observed helper T cell dysfunction. However analysis of infected lymphoid tissue 
revealed infected CD4 T cells were being trapped in the follicular dendritic cell 
network of lymph nodes (Spiegel et al., 1992). The characteristic T cell 
abnormality is a loss of T cell help to HIV itself and to recall antigens. HIV-1 
preferentially infects HIV antigen-specific CD4 T cells (Douek et al., 2002). 
Extrapolation of this observation suggests subsequent recruitment and activation 
of other lymphocyte populations responding to intercurrent infections would lead 
to their infection and deletion leading to impairment of other antigen specific 
responses.
1.4 HIV evasion of the host immune response
HIV is effective in evading the host cell immune response in a number of ways 
apart from the failure of specific CD4 T cell help. A vigorous antibody response is 
observed to HIV however antibodies rarely neutralise primary HIV strains. In 
addition the virus mutates quickly to escape antibody responses (Poignard et al., 
1999). A strong CD8 T cell response to the virus is invariably observed. 
Measurement of antigen specific T cells in the blood using peptide-HLA 
tetrameric complexes has demonstrated a rise in virus-specific CTL concomitant 
with a fall in plasma viremia in acute HIV infection (Wilson et al., 2000). The 
magnitude and specificity of the CTL réponse has shown no clear relationship
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with decline in CD4 count or clinical outcome (Addo et al., 2003). In addition to 
mutation mediated escape from antibody responses the virus mutates rapidly 
from very early on to escape from CTL responses (Price et al., 1997). A 
correlation has been observed between host HLA haplotype and viral sequence 
demonstrating adaption of the virus to immune pressure (Moore et al., 2002).
1.5 HIV Retrovirology
The HIV-1 genome encodes nine open reading frames (Figure la). Three of 
these encode the Gag, Pol, and Env polyproteins, which are subsequently 
proteolyzed into individual proteins common to all retroviruses. The three Pol 
proteins Protease, Reverse transcriptase and Integrase provide essential 
enzymatic function and are also present in the virion. The Gag proteins Matrix, 
Capsid, Nucleocapsid, p6 and Env proteins surface gp120 and gp41 are 
structural proteins making up the virion core and viral envelope.
Figure la. Diagrammatic representation of the HIV genome.
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Lentiviruses differ from other retroviruses in that they encode six genes in 
addition to the three prototypic retroviral genes gag, pol and env. Two of the six 
additional open reading frames, tat and rev, encode factors essential for viral 
replication. The Tat protein that transactivates the HIV long terminal repeat and 
the Rev protein which co-ordinates HIV splicing. The four remaining genes are 
nef, vpr, vpu and vif. They have been termed accessory genes, as their 
inactivation does not completely terminate viral replication in vitro. But studies in 
vivo suggest viruses failing to express any of the accessory genes are disabled 
with decreased replicative capacity in SIV infected monkeys and HIV infected 
humans.
1.6 Lentiviral Life Cycle
A 9 kilobase (kb) RNA encodes the retroviral genome. This is packaged in 
duplicate in the viral particle. A diagrammatic representation of the viral life cycle 
is illustrated in Figure 1b. Virions bind target cells in an interaction that involves 
virion gp120 and CD4 and chemokine receptors on host cells. Following binding 
gp41 undergoes a conformational change that promotes virus-cell membrane 
fusion, facilitating entry of the core into the cell. Uncoating of the virion core 
occurs and the viral nucleoprotein complex consisting of Matrix, Reverse 
Transcriptase, Integrase, Vpr and RNA is exposed. The genomic RNA is reverse 
transcribed to form a cDNA copy. The complex known as the p re integration 
complex (PIC) is subsequently transported to the nucleus. Integrase then 
catalyses integration of the viral DNA into the host chromosome and the DNA is 
repaired. Viral transcripts are expressed from the promoter located in the 5’ long 
terminal repeat (LTR), coordinated by the viral transactivator Tat. Rev 
coordinates splicing of RNA transcripts. Multiply spliced or genomic length 
transcripts are exported to the cytoplasm where they are translated or packaged. 
Following translation, the Gag and Gag-Pol polyproteins become localised to the 
cell membrane. The Env mRNA is translated at the ER. The core particle is 
assembled and an immature virion buds from the host cell surface. During
1A
budding the virion undergoes a morphological change (maturation) that involves 
proteolytic processing of the Gag and Gag-Pol polyproteins by protease. The 
mature virion is then ready to infect the next cell.
Fig Ib.Diagrammatic representation of the HIV Life Cycle
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1.7 HIV RNA
The HIV transcript is approximately 9 kilobases (kb). The first 55 nucleotides 
form the transactivating response element (TAR), the RNA stem loop structure 
required for Tat transactivation. A binding site for primer is located at nucleotides 
182-199 which can anneal to a cellular tRNA and initiate transcription. Genomic 
RNA is incorporated into the virion via a packing signal located at nucleotides 
240-350. This binds Nucleocapsid and is critical for incorporation of genomic 
RNA into the virion (Clever and Parslow., 1997). Between nucleotides 248 and 
271 lies a dimérisation site that facilitates incorporation of two genomic RNAs
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into the virion (Paillart et a!., 1996, Laughrea et al., 1997). At around nucleotide 
290 is a major donor splice site required for generation of spliced transcripts. 
Rev, responsible for HIV splicing binds at nucleotides 7362-7596 at the Rev 
response element. Splice acceptor sites at nucleotides 5358 and 7971 in 
particular allow production of an increased number of spliced transcripts. A Gag- 
Pol frameshifting region comprises an RNA hairpin and slippery sequence 
facilitating -1 ribosomal frame shifting. This translates a fused Gag-Pol 
polyprotein at around 5-10% frequency (Cassan et al., 1994). A polyadenylation 
signal generates the 3’ end of the HIV RNA.
1.8 Function of individual HIV genes 
1.8Î Tat
Transcription complexes initiated at the HIV-1 promoter require the Tat protein to 
enhance the processivity of transcribing polymerases and in some instances 
increase the rate of transcription initiation. Tat is essential for viral replication 
increasing the production of viral mRNAs around 100 fold. The HIV-1 promoter 
contains sites for several transcription factors upstream of the start site including 
NFAT, NF-kB, SPI and TBP (Jones and Peterlin, 1994). Studies substituting 
promoters suggest the TATA box and downstream sequences are important in 
reducing transcription efficiency (Jones and Peterlin, 1994). Tat functions in 
transcription complexes that phosphorylate the C terminal domain of RNA 
polymerase II. The catalytic component in such complexes in CDK9 and Tat 
appears to direct recruitment of CDK9 to such complexes (Zhou and Sharp, 
1996, Parada and Roeder 1996, Yang et al., 1996, Garcia-Martinez et al., 1997, 
Cujec et al., 1997). To function Tat binds TAR, the RNA hairpin located at the 5’ 
end of nascent viral transcripts.
NMR studies of Tat in complex with the TAR loop indicate an arginine rich Tat 
domain help binding to a three nucleotide bulge region of TAR with one arginine 
being primarily responsible for recognition (Puglisi et al., 1992, Aboul-ela et al., 
1995). Contact is made between bases in the side chain and a guanine in the
1R
RNA minor groove and stabilised with additional contacts with the phosphate 
backbone. NMR studies of full length Tat indicate the molecule is relatively 
disordered but contains a short hydrophobic core.
1.8Ü Rev
Viral RNAs are doubly spliced and encode Tat, Rev and Nef when first produced. 
Subsequently singly spliced and unspliced transcripts occur. Rev coordinates this 
process by binding the Rev response element in the env coding region. Rev may 
function to enhance the nuclear export of unspliced mRNAs (Hope et al., 1997). 
Rev is required to export unspliced RNAs that contain a Rev response element 
(Fischer et al., 1995). Rev binding is thought to target the attached mRNA to the 
nuclear export machinery. Rev contains a leucine-rich nuclear export signal 
enabling nuclear-cytoplasmic shuttling and that interacts with hRip/Rab located at 
the nuclear pore (Meyer and Malim., 1994, Fritz et al., 1995, Bogerd et al., 1995). 
CRM1, a nuclear export factor bridges this interaction to facilitate nuclear export 
(Ullman et al., 1997). Mutagenesis of the RRE eliminates Rev activity indicating 
that entry into the splicing pathway may also be important for Rev function. 
Compensatory mutations in U1 snRNA which binds at 5’ splice sites can restore 
activity in this context (Lu et al., 1990). Rev can inhibit splicing by preventing 
entry of additional snRNPs during the later stages of spliceosome assembly 
(Kjems et al., 1993).
1.8Hi Matrix
Matrix is 132 amino acids long and lines the inner surface of the virion membrane 
in the mature virion. Matrix is the N-terminal portion of the Gag polyprotein and 
enables Gag and Gag-Pol precursor polyproteins to target to the plasma 
membrane before assembly of the virion. N terminal myristoylation of Matrix is 
required for membrane localisation. The first 50 residues also appear to be 
important in this regard. Residues 1 to 104 produce 5 a-helices capped by a 
three-stranded p mixed sheet in the matrix crystal structure (Hill et al., 1996). 
Three monomers are arranged as a triskelion and trimérisation appears to be
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required for biological function as mutations in trimérisation residues abrogate 
viral assembly. In addition lysines 26, 27, 30 and 32 implicated in membrane 
localisation are arranged on the membrane-binding surface of the trimer. The 
structure of Matrix would suggest it inserts into the membrane using the 
myristoylation sites and interactions between the basic residues of the 
membrane binding surface and phospholipid head groups.
Matrix plays a role in infection of nondividing cells, a phenomenon peculiar to 
lentiviruses. The role of Matrix in viral entry is not fully elucidated. Initial studies 
implicating a nuclear localisation signal in Matrix that interacts with Rch1 (a 
member of the karyopherin-a family (Gallay et al., 1995)) have not been 
reproduced (Freed et al., 1995, Bukrinskaya et al., 1996, Freed et al., 1997, 
Fouchier et al., 1997).
1.8iv Capsid
Capsid forms the core of the viral particle. Around 2000 molecules of Capsid are 
contained in each virion. The N-terminal domain of Capsid is required for 
infectivity of viral particles by participating in viral uncoating by interaction with a 
cellular protein Cyclophilin A (Luban et al., 1993). Cyclophilin A acts as a 
chaperone. Capsid C-terminus functions in assembly and is important for Capsid 
dimérisation and Gag oligomerisation. Crystal structures of domains of Capsid in 
complex with cyclophilin A have been solved. The C-terminal domain consists of 
an extended strand followed by 4 a-helices. These demonstrate an extensive 
dimer interface (Gamble et al., 1997). A 20 amino acid sequence that is highly 
conserved within all Gag proteins (the major homology region) adopts a compact 
fold in which the four most conserved residues form a stabilising hydrogen bond 
network. Additional hydrophobic residues from the major homology region 
contribute to the hydrophobic core. The major homology region is required for 
viral particle assembly and via interaction with Gag may help incorporate Gag- 
Pol precursors (Srinivasakumar et al., 1995).
1R
1.8v Nucleocapsid
Nucleocapsid coats the viral genomic RNA in the virion. It is 55 residues long and 
contains two zinc finger domains. Nucleocapsid binds and delivers full length 
viral RNAs into the assembling virion after binding the packaging signal. The 
packaging signal appears to consist of three RNA hairpins located around the 
major splice donor site (Clever and Parslow., 1997, Laughrea et al., 1997). 
Nucleocapsid is a basic protein that binds single stranded nucleic acids 
nonspecifically leading to coating of the genomic RNA that protects it from 
nucleases and insulates it within the core. This non-specific binding activity 
enhances other steps in the viral life cycle. These include stimulation of 
integration, promoting annealing of the tRNA primer, melting of RNA secondary 
structures, or by DNA strand exchange reactions during reverse transcription 
(Huang et al., 1997, Guo et al., 1997, Cameron et al., 1997, Carteau et al., 
1997). The NMR structure of nucleocapsid has been determined (Summers et 
al., 1992, Morellet et al., 1992). This shows two well-ordered zinc finger domains 
and a flexible linker in the absence of RNA. Residues important for RNA binding 
in vitro include arginine 7, 32 and lysine 33 however mutagenesis of these 
residues indicates that they have little effect on RNA packaging (Poon and 
Aldovini 1996). The importance of the zinc finger domains has been highlighted 
by treatment with disulfide-substituted benzamide compounds that specifically 
remove zinc (Rice et al., 1995). These compounds inhibit viral replication.
1.8vi p6
The 51 C-terminal residues of Gag, termed p6 is required for incorporation of Vpr 
during viral assembly. This interaction is mediated by a predicted a helical 
structure located near the N-terminus of Vpr and residues 32-39 within p6 
(Kondo and Gottlinger 1996, Lu et al., 1995, Checrone et al., 1996). P6 also 
appears to play a role in viral particle release, amino acids 7-10 being implicated 
in this function (Huang et al., 1995).
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1.8vii Reverse transcriptase
Reverse transcriptase is responsible for converting the viral RNA genome into 
duplex DNA. Reverse transcriptase contains an RNase H domain that cleaves 
the RNA portion of the RNA-DNA hybrids generated during the reaction. Reverse 
transcriptase possesses both RNA-dependant and DNA-dependant polymerase 
activity. Activity is initiated from the 3' end of a tRNAs^ ^® primer annealed to the 
primer binding site near the 5’ end of genomic RNA (Oude Essink et al., 1996). 
After tRNA-primed initiation, reverse transcription involves two DNA strand 
transfer reactions that are catalysed by Reverse transcriptase and are required 
for priming the synthesis of both plus and minus strands (Katz and Skalka 1994, 
Peliska and Benkovic, 1992). Reverse transciptase displays different properties 
during initiation and elongation. It becomes highly processive during elongation, 
post-transcriptional modifications of tRNAs*"^ ® increasing the formation of initiation 
complexes (Lanchy et al., 1996). tRNAs*"^  ^ appears to play a role similar to a 
factor in transcription complexes in this instance.
The crystal structure of unliganded Reverse transcriptase. Reverse transcripase- 
DNA complex and Reverse transcriptase-inhibitor complexes have been solved 
(Rodgers et al., 1995, Esnouf et al., 1995, Hsiou et al., 1996, Jacobo-Molina et 
al., 1993, Kohlstaedt et al., 1992, Ren et al., 1995). Reverse transcriptase exists 
as a heterodimer of residues p66 and p51. Each subunit contains a polymerase 
domain composed of four subdomains named fingers, palm, thumb, and 
connection. Residue p66 contains an extra RNase H domain. The polymerase 
subdomains are arranged differently in the two subunits. P66 forms an active site 
cleft while in contrast p51 forms an inactive closed structure (Wang et al., 1991). 
Reverse transcriptase inhibitors in current use include nucleoside analogues that 
bind to the polymerase active site. The structure of a non-nucleoside inhibitor- 
Reverse transcriptase complex show a hydrophobic binding site near to the 
polymerase active site that rearranges to fit the particular drug and lock Reverse 
transcriptase into an inactive conformation (Kohldstaedt et al., 1992, Ren et al., 
1995). Reverse transcriptase variants resistant to inhibitors have mutations in 
and around the active site and DNA binding cleft suggesting more indirect effects
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as well as simply altering the binding site occur (Ren et al 1995, Tantillo et al., 
1994). Substantial variability in the position of the p66 thumb subdomain is 
revealed by structural studies (Rodgers et al., 1995, Esnouf et al., 1995, Hsiou et 
al., 1996). This could enable conformational rearrangements to occur after ligand 
binding which could facilitate reverse transcription by allowing translocation of 
Reverse transcriptase along nucleic acid or positioning RNase H in active sites.
1.8viii Protease
Immature viral particles are not infectious. Protease cleaves Gag and Gag-Pol 
polyproteins resulting in conformational changes before the viral particle is 
mature. Protease cleaves at several polyprotein sites to produce the final Matrix, 
Capsid, Nucleocapsid and p6 proteins from Gag and Protease, Reverse 
transcriptase and Integrase proteins from Pol. Ribosomal frameshifting 
determines the amount of Gag-Pol incorporated to the virion; usually about 5- 
10% Gag. Factors that influence protease activity have a large effect on virion 
production as assembly and maturation need to be well coordinated. Protease 
activity depends on the concentration of Gag-Pol and the rate of autoprocessing 
that can be influenced by adjacent p6 sequences (Zybarth and Carter 1995). 
Cleavage efficiencies vary among sites controlling the order of appearance of 
processed proteins (Dunn et al., 1994). Overexpression of protease can lead to 
disordered processing and reduced infectivity (Luukkonen et al., 1995). Crystal 
structures of protease in complex with inhibitors have been solved. The dimer 
interface comprises the enzyme active site with each monomer contributing a 
catalytically essential aspartate. A conserved triad Asp-Thr-Gly similar to that of 
other aspartyl proteases is present. The dimer contains flexible flaps that 
descend around the active site on substrate binding. Hydrophobic pockets in 
protease bind amino acid side chains around the active site (Wlodower and 
Erickson., 1993). HIV mutants resistant to multiple protease inhibitors contain 
mutations located within the inhibitor-binding pocket and at distant sites. Some of 
these mutants show reduced catalytic activity (Condra et al., 1995).
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1.Six Integrase
Integrase is a component of the pre-integration complex responsible for 
catalysing a series of reactions facilitating integration of the viral cDNA into the 
host genome. The actual biochemical mechanism of integration is well described 
and is notable due to its close similarity to VDJ recombination. Prior to the 
initiation of the integration process there is assembly of viral DNA on Integrase. 
HIV Integrase recognises specific sequences in the LTRs of viral DNA. Integrase 
removes two nucleotides from each 3’ cDNA end (referred to as 3’ processing). 
This occurs by site-specific endonuclease activity. For this initial 3’-processing 
step, Integrase apparently activates the phosphodiester bond towards cleavage. 
The tailored viral DNA is joined in the next step to host cell DNA in the nucleus 
through an estérification reaction. Here Integrase positions the 3’-0H end of the 
viral DNA for nucleophilic attack on the phosphodiester bond in the host DNA. 
Host cell enzymes catalyse the repair of the resulting gapped intermediate 
although a role here for Integrase is also possible.
The host cell factors required for successful repair of DNA after HIV integration 
are less well understood. Some evidence has recently suggested components of 
the non-homologous end-joining (NHEJ) path of DNA repair are involved. 
Infections of cells mutant in components of the NHEJ path generate reduced viral 
titres due to increased apoptosis of infected cells. In addition Integrase mutant 
viruses are toxic. Also studies with the Reverse transcriptase inhibitor nevirapine 
reveal that synthesis of viral cDNA is required to generate the pro-apoptotic 
signal in these contexts. Bushman and coworkers have recently shown that the 
2-LTR circular form of viral cDNA is absent in infected cells mutant in 
components of the NHEJ pathway (Bushman et al., 2000). In addition NHEJ 
component Ku has been identified in PICS.
Integrase is active as an oligomer, probably a tetramer (Rice et al., 1996). The 
monomer consists of three domains. NMR studies indicate the N-terminal domain 
contains a binding site for zinc and forms a dimer with a largely hydrophobic 
interface (Miller et al., 1995). Each monomer contains a helix-turn-helix structure 
with close similarity to those found in DNA binding proteins. The catalytic domain
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of Integrase contains a D, D (35), E motif conserved among Integrases and 
required for processing and joining reactions. It is proposed to bind the active site 
metal ion (Rice et al., 1996). The crystal structure of the catalytic domain reveals 
a dimeric structure with each monomer containing a five-stranded p-sheet and 6 
a-helices. This structure is similar to that of other polynucleotide transfer 
enzymes (Dyda et al., 1994). As the two active sites are too far apart to permit 
five base pair staggered cleavage of the DNA target either a large conformational 
change occurs on catalysis or Integrase functions in an oligomeric form (most 
likely tetramer) during some reaction steps (Rice et al., 1996, Cai et al., 1997). 
The C-terminal domain forms a dimer of parallel monomers and displays non­
specific DNA binding activity. Each monomer is similar to SH3 domains with a 
five-stranded p barrel with a saddle-shaped groove likely to incorporate double 
stranded DNA (Eijkelenboom et al., 1995, Lodi et al., 1995).
1.8x Vif
HIV-1 virions contain around 10-100 molecules of Vif per average particle 
(Camaur et al., 1996, Fouchier et al., 1996, Liu et al., 1995). Vif mutant viruses 
display attenuated viral DNA synthesis and produce unstable replicative 
intermediates (Cohen et al., 1996, Simon and Malim., 1996). Vif defective viruses 
show defects in infectivity when produced in certain cell types only. These 
observations prompted speculation that it was possible permissive cells produce 
a factor that compensates for a lack of Vif expression or that expression of Vif in 
permissive cells blocks an inhibitor of viral infectivity. Recently a cDNA 
subtraction approach in which the non-permissive cell line served as the “tester” 
and the permissive sample was used as the “driver” revealed a gene, CEM15, 
whose transient expression in cells that do not normally express this recreates 
the non-permissive phenotype. The presence of Vif overcomes this phenotype 
(Sheehy et al., 2002). Interestingly CEM15 displays homology to Apobec-1 and 
Phorbolin-1. Apobec-1 is the cytidine deaminase that is the catalytic subunit of 
the mammalian Apolipoprotein B mRNA editing enzyme (Teng et al., 1993). 
Apobec-1 binds to and edits RNA (Macginnitie et al., 1995) and Vif has been
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reported to bind genomic viral RNA and also to depend on this interaction for 
incorporation into virions (Dettenhofer et al., 2000, Khan et al., 2001, Zhang et 
al., 2000). It is possible CEM15 may affect wf deleted virions through their RNA 
components leading to inability to accumulate reverse transcripts and establish 
provirus in susceptible target cells.
Interestingly the RNA editing enzymes have recently been demonstrated to 
exhibit an addition function to that of RNA editing. Differential gene expression 
studies of somatic hypermutation in B cells have revealed expression of 
activation-induced cytidine deaminase (AID) exclusively in hypermutating cell 
lines (Mutamatsu et al., 2000). AID exhibits sequence homology to RNA editing 
enzymes such as AP0BEC1. AID has also been implicated in immunoglobulin 
class switching and in gene conversion (Nagaoka et al., 2002). Indications that 
these three gene diversification processes might be initiated by a common type 
of DNA lesion and the proposal there is a first phase of hypermutation that 
targets dC/dG pairs suggested AID might function directly at dC/dG pairs. In 
support of this expression of AID in E.coli gives a mutator phenotype that yields 
nucleotide transitions at dC/dG in a context dependant manner. This AID induced 
mutation is accentuated by a deficiency in uracil-DNA glycosylase indicating that 
AID functions by deaminating dC residues in DNA (Petersen-Mahrt et al., 2002, 
Di Noia et al., 2002). Following on from these studies it has been shown 
AP0BEC1, the catalytic component of an RNA editing complex and its 
homologues AP0BEC3C and AP0BEC3G demonstrate DNA mutator activity in 
an E.coli assay. This occurs via dC deamination, each protein exhibiting distinct 
local target sequence specificity (Harris et al., 2002). It is attractive to 
hypothesise that CEM15 is acting in a similar manner on HIV cDNA, perhaps as 
part of an in built host defence mechanism rendering viral replication defective in 
the absence of vif.
1.8xi Vpu
Vpu is another of the HIV accessory genes whose function is not fully delineated. 
Vpu is an 81 amino acid oligomeric integral membrane protein. So far roles of
OA
CD4 degradation, stimulation of virion release and function as an ion channel 
(Lamb and Pinto., 1997) have been assigned to Vpu. Vpu mutant viruses display 
retention of viral particles at the cell surface or localised to intracellular 
membranes (Cohen et al., 1996, Lamb and Pinto., 1997). As Vpu can also 
promote release of heterologous viral particles the mechanism is likely to be non­
specific. Enhancement of particle release requires the N-terminal domain and is 
not influenced by serine phosphorylation (Cohen et al., 1996, Lamb and Pinto.,
1997).
Vpu mediated CD4 degradation occurs in complexes with newly synthesised Env 
glycoproteins (gp160) in the endoplasmic reticulum. Vpu promotes degradation 
of CD4 in these complexes, allowing Env to travel to the cell surface for viral 
particle assembly. The C-terminal of Vpu is important for this effect as well as 
putative a helices in the cytoplasmic tail of CD4 (Tiganos et al., 1997). Vpu may 
interact directly with CD4 in achieving this effect as there be appears to be a 
direct correlation between the extent of Vpu association and relative levels of 
CD4 degradation (Bour et al., 1995). CD4 degradation by Vpu may involve the 
proteosome as lactacystein blocks the effect (Fujita et al., 1997). In addition 
serine phosphorylation of Vpu by a casein kinase-2 related protein is implicated 
(Cohen et al., 1996).
1.8xii Vpr
Vpr, another HIV accessory gene is required for nuclear localisation in non­
dividing cells. Vpr contains a nuclear localisation signal that directs nuclear 
transport in the absence of nuclear envelope breakdown (Cohen et al., 1996). In 
addition to its function in nuclear localisation Vpr can induce cell cycle arrest at 
G2M prior to nuclear envelope breakdown and nuclear condensation. Sustained 
Vpr expression causes apoptosis of host cells. Vpr acts before 
dephosphorylation of Cdc2 by Cdc25, a prerequisite for initiation of cell division 
(Emerman 1996). Amino acids required to initiate G2 arrest are located in the C 
terminus of Vpr. The 65kDa regulatory subunit of Protein phosphatase 2A, a 
serine threonine phosphatase that regulates the transition from G2 to mitosis has
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been shown to bind Vpr (Emerman 1996). Vpr has been shown to influence 
mutation rates during viral DNA synthesis (Mansky 1996) and in addition function 
as an ion channel (Lamb and Pinto, 1997).
1.8xiii Env
HIV-1 particles have a surface of densely arranged envelope spikes. Each spike 
is formed of a trimer of heterodimers of the gpl 20 surface and the gp41 
transmembrane glycoproteins. The entry of human immunodeficiency virus (HIV) 
into cells requires the sequential interaction of the viral exterior envelope 
glycoprotein, gp l20, with the CD4 glycoprotein and a chemokine receptor on the 
cell surface. These interactions initiate a fusion of the viral and cellular 
membranes. Env is synthesised as a fusion incompetent precursor (gp l60) that 
is then proteolytically cleaved into two subunits (the surface subunit gp120 and 
the transmembrane subunit gp41). The surface subunits are responsible for 
recognizing and binding to specific receptors on the host cell. The 
transmembrane subunits contain the fusion peptide at their amino terminus and 
are anchored into the viral membrane via hydrophobic spanning helices. The 
entry event of HIV is accomplished at the cell surface at neutral pH. In common 
with other virus fusion proteins, the N-terminal fusion peptide of the gp41 
ectodomain is followed by a 4,3 hydrophobic (heptad) repeat, characteristic of 
coiled coils (Delwart et al., 1990). The two-heptad repeat sequences form a 
helical core trimer of antiparallel dimers as a six-helix bundle (Chan et al., 1997). 
The N terminal helices form an inner-coiled trimer, whereas the 0 terminal 
helices align in an antiparallel fashion into three hydrophobic grooves on the 
surface of the trimeric core. This six-helix bundle is the fusogenic conformation of 
gp41 and is only formed after HIV-1 g p l20 binds to CD4 receptor (Jiang et al.,
1998).
Although gp120 can elicit virus-neutralizing antibodies, HIV eludes the immune 
system. The X-ray crystal structure of an HIV-1 gp120 core complexed with a 
two-domain fragment of human CD4 and an antigen-binding fragment of a 
neutralizing antibody that blocks chemokine-receptor binding has been solved.
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The structure reveals a cavity-laden CD4-gp120 interface and a conserved 
binding site for the chemokine receptor. The structure provides evidence for a 
conformational change upon CD4 binding, the nature of a CD4-induced antibody 
epitope, and specific mechanisms for immune evasion.
Due to progress made in understanding the mechanism by which gp41 
implements membrane fusion approaches for therapeutic intervention have been 
revealed. Synthetic C terminal peptides have been tested and are potent 
inhibitors of HIV-1 infection at nanomolar levels (Jiang et al., 1993, Wild et al., 
1994). Based on the structural characteristics of the fusogenic confirmation of 
gp41, these C peptides most probably act through a dominant-negative 
mechanism (Chan et al., 1997, Wild et al., 1994, Furuta et al., 1998). 0 peptides 
probably act after the non-fusogenic state has undergone a conformational 
change but in advance of the formation of the stable core structure. This 
‘intermediate’ stage must be in existence long enough for the 0 peptides to bind 
and act in a dominant-negative manner. The wide range of activity of 0 peptides 
against different HIV-1 isolates is explained by the conserved nature of the 
hydrophobic groove to which these peptides bind. At the distal end of this groove 
is a deep cavity, normally occupied by three hydrophobic residues from the 0 
helix. In principle, this cavity is a good target for inhibitors, although peptides that 
do not fill this cavity are still potent inhibitors. A 36-amino acid 0 peptide (DPI78, 
T-20; Trimeris Inc., Durham, USA) is a particularly potent inhibitor of HIV-1 
infection and is currently undergoing clinical trials (Kilby et al., 1998, Kilby et al.,
1999). The generation of mutant viruses that escape T-20 inhibition revealed 
amino acid changes in the N peptide region of gp41 (Rimsky et al., 1998), and it 
is worthy of note that whereas such cavity-binding inhibitors do not yet exist, it is 
considerably more difficult to select viruses resistant to a C peptide that contains 
the cavity-binding region (Rimsky et al., 1998). These observations imply that 
high-affinity ligands targeting the highly conserved coiled coil, and particularly the 
cavity, will have broad-spectrum anti-HIV-1 activity with a reduced propensity to 
develop resistance (Chan et al., 1998). The search for such inhibitors is the 
subject of intense current activity.
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1.9 The HIV nef accessory gene 
1.9i Role of Nef in viral pathogenesis
Nef is a major determinant of HIV virulence. A large deletion in nef attenuates 
HIV pathogenicity in rhesus macaques (Kestler et al., 1991). A similar situation is 
observed in human disease. A cohort of haemophiliac patients infected with nef- 
deleted HIV by blood transfusion are long term non-prog ressors (Deacon et al., 
1995, Kirchhoff et al., 1995, Learmont et al., 1999). A strong selection pressure 
to maintain an intact nef reading frame is observed in both humans and animal 
models. Following infection of macaques with SIV encoding nef with a premature 
stop codon, the virus rapidly reverts to full-length nef. In humans reversion to full 
length nef correlates with disease progression.
Mouse models corroborate these findings. HIV-1 infection of SCID-hu mice 
transplanted with human thymus leads to the massive depletion of double 
positive thymocytes (Bonyhadi et al., 1993). Here full-length viruses replicate 
faster leading to higher viral loads and faster depletion of thymocytes than nef 
deleted viruses (Jamieson et al., 1994). Transgenic mice expressing nef under 
control of CD4 promoter suggest nef directly mediates pathology associated with 
HIV disease. Transgenics expressing full length HIV or nef alone experienced an 
AIDS like disease and died within weeks in contrast to transgenics expressing 
HIV without nef that remained healthy (Hanna et al., 1998).
Nef consists of a single open reading frame that overlaps with the HIV-1, HIV-2 
and SIV 3’ LTR (Cullen et al., 1994). Nef is expressed to highest levels 
immediately after HIV entry. It is the earliest detectable HIV transcript and can 
even be detected in latently infected primary CD4 T cells. Nef is expressed from 
a multiply spliced message and is a myristoylated phosphoprotein of around 206 
amino acids in HIV and 263 amino acids in SIV. This myristoylation has been 
shown to be essential for Nef functions (Chowers et al., 1994, Sawai et al., 1995, 
Aiken et al., 1994). Subcellular localisation studies have demonstrated Nef 
throughout the cytoplasm but in high concentration at the perinuclear region and
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the inner face of the plasma membrane. Recently Nef has been shown to localise 
to lipid rafts in T cells (Wu et al., 2001). In addition Nef has been found in viral 
cores (Kotov et al., 1999).
1.9ii Functions of Nef
Questions concerning the biological function of Nef have been intensively 
investigated. Nef bears little resemblance to any other protein of known function 
and has no orthologs. Early studies suggested a role in the suppression of viral 
replication however these were not reproduced. As a result Nef was christened 
with an acronym for negative factor. Since then Nef has been shown to exert four 
main in vitro functions: CD4 downregulation, MHC 1 downregulation, 
enhancement of virion infectivity and alteration of signalling activity in cells in 
which it is expressed.
1.9iii Nef CD4 downregulation
The ability of Nef to reduce surface expression of CD4 was demonstrated in 
1986 (Garcia and Miller, 1991). CD4 is the primary receptor of HIV and SIV. It is 
expressed on thymocytes, T helper lymphocytes and cells of the 
monocyte/macrophage lineage. A function for this action of Nef was initially 
suggested to prevent deleterious super-infection of HIV infected cells. Recently 
two studies have demonstrated that high levels of CD4 on the surface of HIV 
producing cells inhibit infectivity of released virions by trapping viral envelope 
(Lama et al., 1999, Ross et al., 1999). Other suggested benefits to the virus 
might include the release of Lck that accompanies Nef binding to the CD4 
cytoplasmic tail. Increased levels of free Lck could augment T cell activation, 
creating a milieu favourable for viral gene expression.
Nef down regulates CD4 in all cell lines tested. This effect is not dependant on 
phosphorylation of serine in the CD4 cytoplasmic tail (Garcia and Miller, 1991). 
Nef redirects some CD4 from the Golgi to lysosomes, triggers accelerated 
endocytosis from the cell surface and inhibits CD4 recycling to the cell surface 
targeting it instead to lysosomes.
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The ability of Nef to down regulate CD4 depends on a di-leucine motif in its 
cytoplasmic tail. The fact HIV-1 and SIV Nef do not require identical amino acid 
sequences to down regulate the receptor implies that the receptor may make a 
direct association with its cellular target. This has been demonstrated in several 
systems including the yeast-two hybrid, CD4 capture assays using Nef column 
as bait, and after transfection of insect cells. In addition NMR studies reveal Nef 
binds to a CD4 derived peptide via a di-leucine motif (Grzesiek et al., 1996). This 
was one of the first trafficking interactions to be analysed at a structural level and 
encompasses the 13 amino acid residues in the cytoplasmic tail of CD4 (aa 407- 
419). The di-leucine motif is located at amino acids 413 and 414. Mapping of the 
interaction to the surface of Nef identifies a binding region that forms a 
hydrophobic patch of 10 residues encompassing W57, G96, R106, and 1109. The 
side chains of the W57, L58 and L110 residues are most strongly affected by 
CD4 binding. These residues are highly conserved among Nef variants.
A mechanism for CD4 downregulation has been suggested to involve enhanced 
internalisation of the receptor from the cell surface. Chimeras containing the CD4 
extracellular domain and trans-membrane domain with Nef as the cytoplasmic 
tail are rapidly internalised via clathrin-coated pits and degraded in lysosomes. 
Nef does not contain known CD4 internalisation motifs. It is therefore likely that 
Nef contains motifs capable of forming interactions with components of the 
vesicular trafficking pathways. This appears to be the case as Nef has been 
shown to be capable of forming an interaction with the fx chain of adaptor 
complexes in the yeast-2-hybrid system and in vitro using recombinant proteins. 
Adaptor proteins are hetero-tetrameric complexes that recruit clathrin to the 
cytoplasmic tail of receptors containing endocytosis signals. Several classes of 
adaptors have been documented. AP-1 and AP-2 mediate protein sorting in the 
frans-Golgi network and the plasma membrane. In contrast AP-3 participates in 
direct transport from the Golgi to the lysosomes. AP complexes recognise 
specific motifs in the cytoplasmic tail of surface receptors and direct their 
internalisation. These are either YxxC (where Y is tyrosine, x any amino acid and 
C a hydrophobic amino acid). The component of APs recognising di-leucine
motifs is not clear with studies supporting evidence for interactions with both \i 
and p chains. The jx chain however is known to interact with YxxC motifs. No 
binding to other subunits apart from \x has been demonstrated for Nef.
Nef mutants that cannot recruit AP do not show enhanced endocytosis either in 
trans or when fused to the extracellular and transmembrane domains of the 
receptor. In the case of SIV, Nef mutants in this domain display dominant 
negative characteristics (Piguet et al., 1998). Adaptor protein complexes appear 
to be a major downstream target for Nef in the context of CD4 downregulation. 
Additional Nef binding proteins have been described that appear to influence 
CD4 downregulation. NBP-1 was identified using yeast-2-hybrid. It is capable of 
forming interactions with AP-2 and is probably recruited in clathrin-coated pits in 
addition to blocking CD4 recycling. This protein has homology with the yeast 
vacuolar ATPase (V-ATPase). It is the mammalian homologue of yeast VmalSp. 
This protein can form interactions with the adaptor AP-2 so may be part of a 
multi-protein complex directing CD4 internalisation. Nef also interacts with a 
Thioesterase, an enzyme cleaving thioester bonds. Consequently it is capable of 
altering palmitoyl chains on CD4 and facilitating CD4 recruitment in adaptor 
containing structures. Differences in studies determining Nef binding partners 
implicated in trafficking may have arisen due to low affinities between proteins 
participating in in endocytic trafficking (Marsh and McMahon 1999).
1.9iv Nef MHC I downregulation
Nef can also affect surface expression of MHC 1. This effect is incomplete and is 
limited to HLA A and B alleles. Nef enhances internalisation of these alleles via 
the YxxL motif in their cytoplasmic tail. It therefore does not affect downregulation 
of HLA C alleles that lack this particular motif. This allows Nef to mediate escape 
from NK cell lysis in addition to evasion from CTL attack. The mechanism of Nef 
mediated MHC 1 downregulation is less well explored than that of CD4 
downregulation. It has not been possible to demonstrate a direct interaction 
between Nef and the cytoplasmic tail of MHC 1. In addition motifs in Nef other 
than that required for CD4 downregulation are required for MHC 1
downregulation. The SH3 binding domain in the central region of Nef and a 
series of N terminal residues are required. The exact biochemical basis by which 
Nef mediates this effect is a subject of further investigation. It has not been 
possible to demonstrate a change in tyrosine phosphorylation of the tyrosine 
residue in the MHC 1 cytoplasmic tail in the presence of Nef. Furthermore 
tyrosine kinase inhibitors cannot prevent this phenomenon. Recently it has been 
reported Nef may bind to PACS-1 (Piguet et al., 2000) to mediate retention of 
MHC 1 in the trans-Go\g\. Endosome to Golgi trafficking of Furin and the 
Mannose-6-phosphate receptor is controlled by PACS-1. The Nef PACS-1 
interaction is formed with four glutamic acid residues in Nef (EEEE62). The 
recognition domain for PACS-1 has been shown to be quite promiscuous in that 
many proteins to which PACS-1 binds contain additional phosphorylated 
residues with respect to the defined binding motif (Molloy et al., 1999). HIV-1 Nef 
does not contain sites which can be phosphorylated around this motif. In contrast 
SIV Nef contains an acidic cluster region in the flexible loop that correlates well 
with known PACS-1 interaction motifs. The PACS-1 Nef interaction serves to 
usurp the ARF6 endocytic pathway by a PI3K-dependant process facilitating 
localisation of cell surface MHC 1 in the frans-Golgi (Blagoveshchenskaya et al., 
2002).
1.9v Nef and apoptosis
Nef appears to be capable of subverting pathways of apoptosis in the T cell. Viral 
infection can be expected to trigger apoptosis via several routes. Unscheduled 
DNA synthesis and signals from the cell surface through death receptors 
TNFR1/2 and Fas could activate death programs. HIV gp120 ligation of CXCR4 
on macrophages upregulates membrane bound TNF, which subsequently leads 
to cell death via TNFR in CD8 cells (Herbein et al., 1998). In addition Fas ligand 
upregulation on infected cells could induce death in an autocrine manner through 
Fas ligation.
Nef subverts these responses in different ways. Nef can associate with and 
inhibit the activity of apoptosis signalling regulating kinase 1 (ASK1). ASK1 links
the TNFR and Fas mediated signals via Fas ligand and TNFa to the JNK/p38 
MARK pathways. Overexpression of ASK1 causes apoptosis and expression of 
dominant negative ASK1 will block receptor induced death signals. Thioredoxin 
can inhibit ASK1. Thioredoxin is a redox regulator protein and it seems Nef 
blocks the stimulus dependant release of Thioredoxin from ASK1.
Nef can also block signals regulated by the Bel family. Pro-apoptotic members of 
the family (Bad, Bax, Bak, Bid for example) form heterodimers with members of 
the same family serving to inactivate them (such as Bcl2, Bc I-X l, Bcl-w). The pro- 
apoptotic factors such as Bad are phosphorylated on serine residues releasing 
Bcl-2 for pro-survival activity (Gross et al., 1996). Ligation of growth factor 
receptors or cytokines results in activation of PI3-K and Akt kinases that can 
directly phosphorylate Bad. Middle T antigen of Polyoma virus activates this 
pathway of anti-apoptotic signalling (Wolf et al., 2001). Nef binds and activates 
PI3-K like middle T antigen to activate the Nef associated PAK kinase. The Nef 
-PI-3-PAK complex phosphorylates Bad resulting in a block of apoptosis induced 
by serum starvation and HIV replication itself. Nef anti-apoptotic signalling 
increases viral particle release and enhances viral replication.
1.9vi Nef enhancement of virion infectivity
Two mechanisms have been proposed for the effect of Nef on HIV infectivity. 
One of these is the downregulation of CD4 that results in decreased 
sequestration of virion Env. Nef stimulates HIV-1 infectiousness in a CD4 
dependant manner (Chowers et al., 1995). Nef defective viruses produced from 
GD4 negative cells are about ten times less infectious in single round infectivity 
assays as their wild type counterparts. Nef mutated virions demonstrate a severe 
growth defect in PBMC infected while resting and subsequently activated (Spina 
et al., 1994, Millar et al., 1994).
Analyses performed on single rounds of infection reveal that Nef promotes the 
events that immediately follow viral entry, thereby stimulating the efficiency of 
HIV proviral DNA synthesis. A recent study has revealed that nef transcripts can 
be detected even prior to proviral nuclear translocation and integration. The route
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by which the virus infects cells appears to be important in this effect. HIV-1 
particles pseudotyped with the G protein of vesicular stomatitis virus do not 
require r?ef to achieve similar levels of infection as the nef positive virus. This 
suggests direct targeting to the endocytic path may play a role. Possibilities 
include that Nef stabilises the reverse transcription complex or influences events 
associated with viral uncoating.
Different domains are required for this effect of Nef from those implicated in CD4 
downregulation. These include a sequence between amino acids 17 and 26, the 
SH3 binding domain and the PAK kinase recruitment domain. This di-arginine 
motif contributes to CD4 dependent and independent enhancement of virion 
infectivity. Another explanation for Nef enhancement of infectivity has been 
described. Nef has a proteolytic cleavage site for the viral protease. About 60- 
200 copies of Nef are incorporated in each virion-usually the cleaved form. The 
C-terminal domain of Nef incorporated in viral particles is liberated from the N- 
terminal domain. Mutants in the proteolytic cleavage site (WL58) retain the ability 
to increase infectivity. Replacing HIV-1 Nef in trans by SIV Nef which is not 
cleaved by the HIV-1 protease does not affect infectivity. Therefore it is unclear 
what roles the virion incorporation of Nef and its cleavage by the viral protease 
plays in the life cycle.
1.9vii Nef alteration of T cell signalling
Nef is the earliest expressed HIV transcript and can be detected before HIV 
integration indicating a role in the earliest stages of the viral life cycle. The HIV 
long terminal repeat (LTR) contains transcriptional regulatory elements identical 
to those of T cell inducible genes. It has been hypothesised if Nef could affect 
signal transduction paths normally activated after T cell stimulation it might affect 
HIV replicative capacity as HIV replicates to high levels in activated T cells. 
Despite many studies addressing this question definitive evidence for a role for 
Nef in this context has been lacking.
Nef contains a conserved poly-proline motif that acts as an SH3 binding domain. 
Nef recognises the SH3 domain of Hck and Lyn PTKs via this domain (Lee et al..
1996, Lee et al., 1995, Saksela et al., 1995). It has been reported to interact with 
Lck via its central domain and N-terminus (Baur et al., 1997, Collette et al., 1996, 
Greenway et al., 1996). In addition Nef is capable of sequestering Lck into the 
cytoplasm away from the CD4 cytoplasmic tail in the process of CD4 
downregulation (Aiken et al., 1994, Baur et al., 1997). Nef also forms interactions 
with PAK1 and PAK2 (Sawai et al., 1994, Sawai et al., 1995, Lu et al., 1996, 
Nunn et al., 1996). PAK kinases induce cytoskeletal alterations, bind to GTPases 
cdc42 and RAC1 and signal through the MAP kinase cascade. In addition 
interaction of Nef with protein kinase 0 6 has been reported (Smith et al., 1996).
Despite the documentation of these multiple interactions it has not been possible 
to demonstrate a definitive functional effect of Nef on T cell signalling. Several 
Nef transgenics have been engineered. Nef-expressing transgenic thymocytes 
show enhanced calcium flux and increased mitogenic responses to anti-CD3 T 
cell stimulation. A Nef transgenic where nef was expressed under control of the 
CD4 promoter enhancer element demonstrated thymocyte hyperactivation with 
increased tyrosine phosphorylation of LAT and MAPK after T cell stimulation. In 
addition rare mature peripheral cells showed increased expression of activation 
markers. CD8-Nef chimeras were used to study Nef affect on signalling in Jurkat 
T cells. Surface expression of such chimeras resulted in induction of NFk B 
luciferase activity, accumulation of tyrosine phosphorylated proteins and surface 
expression of T cell activation markers. Furthermore prolonged expression of 
these chimeras on the T cell surface resulted in cell death by apoptosis (Baur et 
al., 1994). Not all CD8-Nef accumulated at the cell surface. In cells where it was 
sequestered in the cytoplasm inhibition of T cell signalling was observed.
Monkey models have lent further support for a function of Nef in T cell activation. 
SIV Nef variants containing amino acid sequences acting as functional 
immunoreceptor tyrosine-based activation motifs (ITAMS) replicated to high 
levels in unstimulated PBMC (Du et al., 1995). A study in an IL2-dependant 
rhesus monkey T lymphoid cell line infected with herpes virus demonstrated in 
the absence of IL2 SIV strains containing nef from SIV or HIV grew 100 times
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more efficiently than nef deleted counterparts. In addition the nef positive viruses 
could induce IL2 in this context (Alexander et al., 1997).
More recently Nef has been shown to localise to lipid rafts in T cells via its 
myristoylated N terminus (Wu et al 2001, Schrager et al., 2000). Lipid rafts 
accumulate signalling mediators after T cell activation and are thought to 
represent a platform for initiation and maintenance of T cell activation signalling 
cascade. Two studies have demonstrated a priming role for Nef in T cells. In the 
presence of Nef, activity of NFk B, NFAT and API luciferase reporters is 
significantly increased after exogenous stimulation in comparison to cells lacking 
Nef. In contrast other studies have inferred Nef can inhibit activation (Collette et 
al., 1996, Band res et al., 1994, Carreer et al., 1994, Collette et al., 1996, Collette 
et al., 1996, lafrate et al., 1997, Neidermann et al., 1993, Neidermann et al., 
1992).
1.9viii Nef structural studies
It has not been possible to determine the complete structure of HIV Nef however 
components have been solved by either NMR or crystallography. Nef consists of 
a highly conserved and well-folded core domain of around 120 residues and a 
genetically diverse and structurally flexible N-terminal arm of around 70 residues. 
The core domain adopts a stable tertiary fold. This core forms an a-p domain in 
which a central anti-parallel p sheet of four strands (pA-pD) is surrounded N- 
terminally by two long anti-parallel a helices (aA and aB) and C-terminally by two 
short a helices (aC and aD). The proline rich sequence is located upstream of 
aA and adopts a left-handed helix of the type two polyproline II. The structure of 
this core domain has been solved by both NMR and crystallography and by 
crystallography in complex with Src kinases. Most signalling molecules capable 
of forming interactions with Nef require this domain for binding. Nef has a high 
(nanomolar) affinity for the SH3 domains of Hck and Lyn, and a lesser 
(micromolar) affinity for the SH3 domains of Lck, Fyn and Src. The functional 
outcome of interactions with the 8H3 domains of various kinases does not 
appear to correlate with kinase activity. Nef has been shown to activate Hck but
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not Lyn or Src. It has also been shown to decrease kinase activity of Lck and 
Fyn.
The core domain of Nef has been shown to mediate oligomerisation and Nef 
dimers and trimers have been demonstrated in vivo and in vitro. Their 
significance is unclear. Oligomerisation has been shown to mediate signalling 
and endocytosis in other contexts and as such may be important for Nef function. 
The quaternary structure of Nef might facilitate functional connections with 
signalling or vesicular trafficking components.
The core domain is involved with interactions with PAK kinase, TCRÇ and the 
Thioesterase. Another feature of the Nef structure are the two flexible regions 
that comprise 50% of the polypeptide chain. These occur in the core domain and 
the N-terminal arm. This loop connects with three binding motifs a di-leucine 
based internalisation motif is found to the middle of the loop and associates with 
Adaptins. Closer to the N-terminal of the loop a di-acidic sequence has been 
shown to be necessary for the association with Nef and p-COP. Finally a 0- 
terminally located cluster is required to localise Nef with both AP complexes and 
the v-ATPase. As the core domain sequence is divergent in sequence but 
conserved in length a proposed function is the presentation of these motifs at a 
defined distance from the folded core domain.
An unusual feature of Nef structure is the presence of several flexible regions 
that is not common for a cytoplasmic protein. This could explain so many of the 
diverse reported interactions of Nef as the flexible regions can provide an 
extensive accessible surface.
1.10 T cell activation and signalling
T cell activation following ligand recognition is a central part of the immune 
response. T cell receptor (TCR) heterodimers mediate this process. These 
resemble antibodies in their ability to create vast numbers of different variable (V) 
region sequences through DNA rearrangement. Most T cell types recognize 
specific fragments of antigens bound to major histocompatibility complex (MHC)
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molecules displayed on the surface of other cells. This ability to survey 
degradation products of antigens makes for a detection system that is intrinsically 
difficult for pathogens to avoid, as all proteins must eventually be degraded. Very 
few peptide-MHC complexes on an antigen-presenting cell are needed to trigger 
a T cell response allowing for a high degree of sensitivity. In order to understand 
how engagement of the TCR to a ligand activates a T cell, attention has focused 
on the CDS molecules (CDS e, y, ô and t)  that are assembled together with the 
TCR heterodimer and possess ITAM motifs that are phosphorylated on activation 
These phosphoryalted ITAMS may subsequently interact with SH2 domains 
(Reth, 1989). The TCR polypeptides themselves have very short cytoplasmic 
tails, and it appears that all proximal signalling events are mediated through the 
CDS molecules. TCRs are organized in dimeric units (Terhorst et al., 1996), and 
evidence also indicates there are two TCR heterodimers per unit (Fernandez- 
Miguel et al., 1999, Terhorst et al., 1996). The variety and apparent redundancy 
of these polypeptides probably relate to the varying signals that a T cell must 
receive in order to mature and survive. In particular, immature T cells are heavily 
selected in the thymus both for a successful TCR rearrangement (the pre-TCR- 
CD3 complex) and later for complete TCRs that react weakly to self-peptide- 
MHC complexes, which is important for avoiding selection of self-reactive T cells. 
The selected T cells then require additional stimulation in the periphery from such 
ligands in order to survive. This selection and maintenance process is apparently 
necessary to establish a TCR repertoire that is both predisposed toward a 
particular MHC complement and in a high state of readiness to respond to the 
appropriate foreign antigen when it comes along.
For many years it has been thought that the principal trigger for T cell activation 
is the tyrosine phosphorylation of CD3 molecules, particularly CD3, brought 
about by TCR crosslinking and mediated by Lck (Kane et al., 1999). However it 
has recently been shown a slightly earlier event involving a conformational 
change and subsequent exposure of a proline-rich region of the cytoplasmic tail 
of CD3 may be involved (Gil et al., 2002). Exposure of this region allows the 
adaptor protein Nek to bind. This can occur in isolated TCR-CD3 complexes, with
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stimulation by monovalent antibodies, and independent of early tyrosine 
phosphorylation. The association of Nek to CDS appears to be necessary for 
proper T cell activation, as a dominant negative construct of Nek inhibits the 
ability of T cells to form conjugates to other cells in response to antigen, and 
disrupts aspects of synapse formation, cytoskeletal reorganization, and cytokine 
production. Thus, it appears that there are at least two distinct pathways whereby 
TCR engagement triggers activation in T cells: tyrosine phosphorylation of ITAMs 
by Lck and Fyn, and a conformational change in CDS leading to Nek recruitment, 
with both of these occurring within seconds of TCR engagement with ligand. 
These signals probably converge at some point downstream, with a likely point of 
convergence being the one of the signalling molecules SLP76 or LAT both 
essential for T cell activation.
1.11 Functional genomics and microarray technology
Completion of the human genome sequencing project has paved the way for 
studying biological phenomena on a genome wide basis. Various methodologies 
are being evolved with this aim in mind. DNA microarrays provide a means of 
analysing transcriptional responses on a large scale. At present no whole 
genome chip exists for the human genome although it is inevitable this will be 
developed.
Microarrays consist of precisely positioned DNA fragments (probes) at high 
density on a solid support. Three main types of microarray are filter arrays, 
spotted glass slide arrays and in situ synthesised oligonucleotide arrays. In gene 
expression microarrays either synthetic oligonucleotides or cDNA fragments are 
used as probes. Ideally probes should be sequence validated, possess unique 
sequence, show minimal cross-hybridisation to related sequences and provide a 
comprehensive representation of the expressed fraction of a genome including 
splice variants. Sources of probe fragments used for arraying have been 
bacterial cDNA or bacterial artificial chromosome (BAG) clone sets, although sets 
of long oligonucleotides are increasingly becoming a viable alternative. There
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have been many shortcomings in libraries for complex organisms. For example 
libraries available for mice and humans contain a certain amount of redundancy, 
contamination and misannotation. Many initial cDNA clone sets were 
compromised by contamination with T1 phage, by containing multiple clones in 
individual wells and by incorrect sequence assignment (Halgren et al., 2001). For 
some microarray applications such as the sensitive detection of genomic losses 
in tumour cells large insert clones such as BACS are more appropriate than 
cDNAs. Human BAG clone sets were generated as part of the human genome 
sequencing project. These libraries contain as much as a tenfold redundancy 
across genomes, requiring individual clones to be selected to reduce clonal 
overlap for microrraying purposes.
DNA for arraying is typically prepared from clone sets by high throughput PGR 
rather than purification of individual plasmids. There are considerable logistical 
difficulties in handling large numbers of bacterial clones making the use of 
oligonucleotide arrays an attractive alternative. The design of oligonucleotides for 
arraying is not simple (Relogio et al., 2002, Rouillard et al., 2002). In practise the 
use of commercially available arrays is favoured due to cost considerations and 
yield of full length long oligonucleotides which can be suboptimal.
Spotted arrays are mostly printed on glass. Glass slides are the favoured solid 
support for probe immoblisation as they allow a variety of surface chemical 
modifications, are resistant to high temperature, are cost effective, possess low 
fluorescence, are transparent and rigid. Many initial arrays contained poly-L- 
lysine as the substrate due to low cost and ease of manufacture. The type of 
substrate used can affect the signal intensity, degree of background and 
durability of the slide. Substrate choice is often dependent on whether cDNAs or 
oligonucleotides are being printed.
The main application of microarrays has been that of comparitive expression 
profiling in different contexts. Examples would be comparisons of diseased 
versus normal tissues (Lock et al., 2002), studying gene regulation during 
development (Miki et al., 2001), following changes after cell stimulation (Iyer et 
al., 1999) and profiling neoplastic lesions (Alizadeh et al., 2000, Bittner et al..
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2000, Dhanasekaran et al., 2001). Microarrays have also been used to screen 
for mutations (Ahrendt et al., 1999), comparative genomic hybridisation (Pollack 
et al., 1999), chromatin immunoprécipitation (Lo et al., 2001, Shannon and Rao., 
2002), genotyping (Lindblad-Toh et al., 2000) and for localised cell transfection 
(Ziauddin and Sabatini, 2001). Experiments using glass slide microarrays 
involving competitive hybridisation of two targets are often carried out by labelling 
each target (test and reference) with a specific fluorescent dye (Cy3 or Cy5). 
Experiments may involve individual pairwise comparisons or compare one 
sample against all others. Labelling protocols are based on the reverse 
transcription of mRNA either from highly purified poly(A) mRNA or total RNA 
extracts. Many protocols have been developed for the extraction of high quality 
RNA that remove contaminating polysaccharide, protein and RNases. Initial 
protocols involved direct labelling. Here a poly(dT) primer is used to prime 
mRNA in the presence of fluorescently labelled nucleotides (typically Cy3 or Cy5 
conjugated dCTP or dUTP) or radioactive isotopes. As Cy3 and Cy5 are bulky 
their incorporation using standard enzymes is rather inefficient. It has also been 
noted that rates of incorporation can differ between dyes resulting in biases 
between dye incorporation (Yang et al., 2002). The development of reverse 
transcriptases that allow more efficient incorporation of flourescently labelled 
oligonucleotides should bypass this problem. Other methods of sample labelling 
include amino allyl labelling. Here an amino modifed dUTP is used instead of a 
prelabelled nucleotide. After reverse transcription the free amine group on the 
amino allyl modified dUTP can be coupled to a reactive A/-hydroxysuccinimydl 
ester flou rescent dye. This technique has benefits of better sensitivity and 
absence of dye biases, but requires more time. A large amount of RNA is 
required for sample labelling. RNA amplification protocols have been developed 
to overcome this limitation. Many of the methods are based on “Eberwine” 
amplification (Van Geler et al., 1990).
Conventional methods of hybridising arrays such as under coverslips or in 
chambers can give variable results. This can be due to problems with probe 
distribution resulting in differences in gene expression dependent on spatial
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position on the array (Colantuoni et al., 2002). Newly designed commercial 
instruments have the potential to undertake automated hybridisation improving 
reproducibility. After hybridisation microarrays are scanned using using either a 
scanning confocal laser or charge coupled device camera based reader.
Microarray experiments are providing unprecedented quantities of genome-wide 
data on gene-expression patterns. The completion of the sequencing of a large 
number of prokaryotic and eukaryotic genomes facilitates attempts to functionally 
classify predicted genes. Microarray analysis promises to contribute to the 
functional annotation of genomes and has already provided a wealth of genome- 
wide expression data. Much attention has been focused on experimental 
protocols for microarray studies, but the strategies for data analysis have a 
profound effect on the interpretation of the results. Expression data from each 
experiment must first be normalized to account for systematic experimental 
variation, including unequal dye incorporation and detection efficiencies. 
Normalisation of microarray data represents a key component of data analysis. It 
is not uncommon for a certain amount of systematic variation to exist in the data 
produced from experiments owing to the complex process of production and 
hybridisation of spotted microarrays. Various normalisation algorithms are 
available for analysis and the choice of that used is based on the type and 
degree of systematic biases that are encountered in a particular experiment. 
These could be biases in dye incorporation during labelling, variations in probe 
distribution during hybridisation, topographical slide variation or scanner induced 
bias (Karsten et al., 2002). Microarray analysis software incorporates options for 
normalisation. At present there are few normalisation algorithms that adjust for 
irregular spatial distribution across the surface of an array. After correction of 
biases toward a particular channel and global variation in mean expression has 
been adjusted for there can remain evidence of a nonrandom distribution of the 
differentially expressed genes present. Two options are available for addressing 
this. The SNOMAD method attempts to correct both intensity and spatial bias 
(Colantuoni et al., 2002). Pin-group normalisation uses information obtained from 
the grids and sub-grid layout to carry out a LOWESS based transformation of the
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data. Both are implemented in the open-source R statistical language. It is hoped 
further development of normalisation techniques will improve correction for 
systematic variation. For comparison between experiments, data is often first 
filtered to select a subset or to exclude genes for which there is much missing 
data. A distance metric must then be chosen, which determines how similarity is 
measured between gene-expression patterns. Genes and experiments can then 
be grouped using various computational methods. Each step can influence how 
the expression data are grouped. Clustering algorithms, which are the most 
widely used approaches to analysing gene expression, can be classified as 
hierarchical or non-hierarchical (self-organizing maps (SOMs), /c-means 
clustering and principal component analysis), agglomerative (hierarchical) or 
divisive (/c-means, SOMs), and supervised (support vector machine) or non­
supervised (hierarchical and /c-means clustering, SOMs). The choice of data 
analysis strategy is determined by the purpose of the microarray experiment and 
the available knowledge of the biology of the system under investigation.
1.12 Proteomics
With complete genome sequences now available for several prokaryotic and 
eukaryotic organisms molecular and cellular functions for these genes must be 
assigned. The field of proteomics has evolved to address this and includes in its 
goals the development and application of methods for genome wide analysis of 
protein expression and function. The creation of systems for rapid analysis of 
proteins will accelerate the process of ‘functionalisation’ of these biomolecules. 
While proteomics can be conceptually viewed as the protein equivalent of 
genomics a myriad of technical problems exist for the scientific investigation of 
proteins that present challenges beyond that encountered in genomics. For 
example unlike RNA or DNA proteins do not inherently possess well defined 
high-affinity and/or selectivity of binding partners. Gene microarray technology 
utilises the interactions oligonucleotides share with their anti-sense partners. 
Protein microarrays however must be designed to use a specific capture reagent
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for each protein. Proteins exhibit a range of biochemical properties exceeding 
that encountered with DNA and these are linked to the precise 3D structure of 
folded polypeptides. The diversity of traits exhibited by proteins, ranging from 
extreme pi values to membrane association to post-translational modification 
mean that a universal method to handle and process proteins is not currently 
available. Another large hurdle is the characterisation of low abundance proteins 
as in contrast to RNA or DNA proteins cannot be amplified by methods 
analogous to PCR.
A mainstay of proteomic analysis has been the 2D gel and mass spectrometry 
(MS) approach. MS has become a primary tool for proteomics as it is capable of 
sensitive and rapid protein identification combined with quantitation. While it is 
possible to identify thousands of proteins from microgram sample quantities in a 
single day the need for increased capability is required. Central to success of the 
MS approach is the separation methodology primarily used. 2D-gel separations 
are the traditional approach however liquid phase separations are growing in 
use. These are primarily based on liquid phase chromatography (LG). At present 
most LC-MS uses an electrospray ionisation (ESI) interface to produce ions from 
liquid samples and matrix assisited laser desorption ionisation (MALDI) is most 
commonly used for the analysis of individual processed samples.
1.13 RNA interference
RNAi has proved to be a useful reverse genetic tool in the context of assigning 
function to individual genes. Systematic RNAi screening has been used to assign 
function to 13.9% genes on chromosome I in C.elegans (Fraser et al., 2000). In 
addition it has been employed in Drosophila to identify genes involved in 
phagocytosis (Ramet et al., 2002) and in Trypanosoma bruoei io establish 
glycolysis as modulating glycoprotein expression (Morris et al., 2002).
However in mammalian cells use of dsRNA as a reverse genetic tool must be 
undertaken using short sequence specific dsRNAs. Innate immune responses to 
microorganisms developed by higher eukaryotes include the recognition of
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dsRNAs. dsRNAs represent a replicative intermediate for many viruses not 
normally present in eukaryotic cells. In mammalian cells this response involves 
the production of Interferon. Interferon can reduce viral spread by inhibiting viral 
gene expression and causing apoptosis of infected cells. A key characteristic of 
RNAi is its sequence specificity. mRNAs homologous in sequence to the dsRNA 
are specifically degraded.
Work in Drosophila has contributed to the current mechanistic understanding of 
RNAi (Zamore et al., 2000, Elbashir et al., 2001). DsRNAs introduced to 
Drosophila cells are cleaved into 21 or 22-nt dsRNAs with a 2-nt or 3-nt overhang 
referred to as small interfering RNAs (siRNAs). DICER, an RNase Ill-like enzyme 
mediates this cleavage (Bernstein et al., 2001). These siRNAs are incorporated 
into a multiprotein complex of approximately SOOkD known as the RNA-induced 
silencing complex (RISC). RISC may undergo an ATP dependant activation step 
that involves unwinding of the double stranded siRNA component to give a single 
stranded RNA guide that targets RISC to homologous RNAs. Binding of the 
homologous mRNA to RISC occurs and a ribonuclease component cleaves the 
target mRNA at the centre of the region complementary to the guide RNA. The 
cleaved RNA is degraded by cellular exonucleases after release of RISC. 
Synthetic siRNAs can be incorporated into RISC and induce targeted mRNA 
degradation (Elbashir et al., 2001). DsRNAs less than 30 bp do not induce an 
interferon response and as a result siRNAs can effectively inhibit gene 
expression in mammalian cells.
1.14 Summary
The work described in this thesis investigates the function of HIV Nef. The aims 
of the work were to clarify the in vivo relevance of described Nef in vitro protein- 
p rote in interactions by examining the potential downstream consequences of 
these interactions in terms of gene expression. Large scale gene expression 
profiling was used to investigate gene expression changes induced by Nef in 
CD4 T cells as a consequence of T cell signalling. The demonstration Nef can
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induce gene expression changes compatible with T cell activation using this 
approach led to an attempt to define the molecular mechanism by which this 
occurs.
Nef is one of the HIV proteins for which there is currently no drug inhibitor. Better 
drug treatments are required to attenuate the progression of HIV. Investigating 
how Nef interacts with host cell proteins to induce HIV pathogenicity may permit 
design of inhibitors. It has recently been demonstrated engineered cyclic D- 
peptides can inhibit HIV-1 entry by targeting a prominent pocket on the surface of 
the NH2-terminal coiled coil of the pre-hairpin intermediate (Root et al., 2001). 
These observations have led to phase I/ll clinical evaluation of the Trimeris C 
peptide, T-20 as an inhibitor of HIV entry. T-20 is the first of a new target class 
for the treatment of HIV-1 infection. The proof-of-concept for this target has 
fuelled the search for more drug-like candidate molecules that act in a similar 
manner. Inhibition of the effect of Nef on viral productivity and on MHC 1 down­
regulation would have obvious benefits for the infected individual. In addition 
delineation of the molecular mechanism of action should yield insight into 
undiscovered aspects of vesicular trafficking and signalling.
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Chapter 2
Materials and Methods
2.1 Source of Chemicals and Enzymes
Chemicals were purchased from Aldrich, BDH, or Sigma and were of Analytical 
Reagent or Molecular Biology grade. Bacterial media products were from Oxoid, 
tissue culture materials from Gibco-BRL, agarose was from FMC Bioproducts, 
pre-mixed acrylamide/bis-acrylamide (37:5:1) was from Amresco, radioisotopes 
were purchased from Amersham. Oligonucleotides were purchased from Gibco. 
Enzymes were purchased as follows:
Superscript II reverse transcriptase-Gibco-BRL 
Calf Alkaline phosphatase -Boehringer Mannheim 
RNase -free DNase I -Boehringer Mannheim 
Taq DNA polymerase-Boehringer Mannheim 
Restriction enzymes-Boehringer Mannheim 
T4 DNA ligase-Boehringer Mannheim
2.2 Solutions
Solutions were prepared in water from an Elga Primostat purification system, and 
were sterilised by autoclaving. Solutions for RNA work were treated with DEPC 
for 15 hours at 37°C and autoclaved.
TFB 1
30mM KOAc pH 5.8 
lOOmM KCI2 
lOmM CaCl2 
50mM MnCb
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15%v/v glycerol 
TFB 2
10mM MOPS pH 6.8 
75mM CaCb 
10mM KCI2 
15% v/v glycerol
L Broth
1% w/v bactotryptone 
1 % yeast extract 
85mM NaCI
TE
lOmM Tris-CI pH 8.0 
ImMEDTA
5X TBE
500mM Tris-borate 
lOmM EDTA
SDS running Buffer 
lOOmM Tris-CI pH 8.3 
960mM Glycine 
0.5%w/v SDS
10x Form amide Loading Buffer 
lOmg/ml Bromophenol Blue 
lOmg/ml Xylene Cyanol 
lOmM EDTA 
80% v/v Formamide
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10X denaturing solution 
1 M NaOH 
lOmMEDTA
2X neutralizing solution (1 M NaH 2 PO 4 [pH 7.0])
27.6 g NaH 2 PO 4 *H 2 O
Add 190 ml of H 2 O. Adjust pH to 7.0 with 10 N NaOH if necessary. Add H 2 O 
to 200 ml.
20XSSC
175.3 g NaCI
88.2 g Na 3 Citrate*2H 2 0
Add 900 ml of H 2 O. Adjust pH to 7.0 with 1 M HOI if necessary. Add H 2 O 
to 1 L.
20%SDS 
200 g SDS
Add H 2 O to 1 L. Heat to 65°C to dissolve.
Wash Solution 1 
2X SSC 
1%SDS
Wash Solution 2 
0.1XSSC 
0.5% SDS
FACS buffer-RBA
PBS
1%BSA
AQ
0.1% sodium azide
2.3 Restriction Digests
Digests were performed in Boehringer Mannheim buffers using the optimal buffer 
for single digests and the best compromise buffer for double digests. Digestion 
products were analysed by agarose gel electrophoresis. If fragment extraction 
was required DNA extraction kit from Qiagen was used.
2.4 Electrophoresis
DNA markers
Agarose gel markers XIV and XVII were obtained from Boehringer Mannheim. 
Agarose gel electrophoresis
Samples were run in IX  Orange G buffer on 1-2% agarose TBE gels containing 
l^ig/ml ethidium bromide with current limiting at 200mA (minigels). DNA was 
visualised on a UV transilluminator (Stratagene model 2040EV), and 
photographed using a UVP digital camera system. When fragments were being 
isolated the gel was visualised using low wavelength UV and excised from the 
gel with a clean razorblade. DNA was isolated using gel purification kit from 
Qiagen.
SDS Polyacrylamide gel electrophoresis
50ml native and denaturing (7M urea gels) were prepared m ix  TBE using 40% 
acrylamide: bisacrylamide (19:1). Polymerisation was initiated with the addition of 
50fx TEMED and 500^1 10% ammonium persulphate, and the gel was cast
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between two glass plates. Gels were run at 80V through the stacking gel and 
160V thereafter in SDS PAGE running buffer.
2.5 Cloning
Vector preparation
3fxg of vector DNA was linearised by addition of 6fxl DNA, 3fxl restriction enzyme 
digest reaction buffer, 3^ 1 restriction enzyme and 18p1 sterile distilled H2O. This 
was incubated for 3 hours at 37°C and subsequently heat inactivated at 70°C for 
2 minutes. After cooling on ice for 60 seconds 2\i\ of alkaline phosphatase was 
added together with 4\i\ lOx reaction buffer and 4^1 of H2O. This reaction was 
incubated for a further 30 minutes at 37°C before running on TBE agarose gel 
and DNA purification using Qiaquick (Qiagen) purification reagents.
Ligations
These were carried out using rapid ligation kit (Boeringer Mannheim). Ipil vector 
DNA was mixed with 3^ 1 insert DNA, 2|il DNA dilution buffer and 4pil H2O. This 
was mixed with lOfxl ligation buffer and finally Ipil T4 DNA ligase. The reaction 
was allowed to proceed at room temperature for 15 minutes prior to bacterial 
transformation.
2.6 Bacterial Transformation
Bacterial strains
DH5a F’/endA1 hsdR17 (9rk"m/) supE44 thi-1 recA1 gyrA (Nal"") relA1
A (laclZYA-argF)UI69 deoR (cl)80dlacA(lacZ)M15)]
XL-1 Blue F::Jn1 OproA+B+laclq A(iacZ)M15/recA1 endA1 gyr A96 (Na^)
thi hsdR17 (rk'mk"") supE44 relA 1 lac
Preparation of competent cells
A1
A single colony of DH5a or XL-1 Blue was inoculated into a 50ml culture in LB 
broth and grown overnight. 10ml of this was used to inoculate 500ml cultures that 
were grown to obtain an ODeoo of 0.5. The culture was cooled and the cells 
harvested after centrifugation (10 minutes at 5000 rpm) in a pre-cooled JA-10 
rotor using a Beckman J2-20 centrifuge. The cell pellet was then resuspended in 
100ml pre-chilled TFB 1 and incubated on ice for 30 minutes then harvested as 
before. Cells were resuspended in 20ml TFB 2 and incubated for 15 minutes 
before 500fxl aliquots were frozen at -70°C.
Transformation with plasmid DNA
Aliquots of frozen competent cells were thawed on ice. 200fil of cells were mixed 
with 2|il of ligation reaction and incubated on ice for 40 minutes, heat shocked at 
42°C for 90 seconds and then returned to ice for 2 minutes. The cells were 
added to 1ml of LB and shaken at 37°C for 30 minutes. The cells were isolated 
by centrifugation and spread on pre-warmed selective plates of either LB 
containing 50|ig/ml Ampicillin or Kanamycin. These were incubated at 37 °C 
overnight.
2.7 DNA isolation
Small and large scale DNA isolation was carried out using Qiagen DNA 
extraction kits.
2.8 DNA Sequencing
Automated sequencing reactions using an Applied Biosystems 3373 stretch DNA 
sequencer were performed as recommended.
2.9 Cell stimulation and Drug treatment
A9
For stimulation with anti-CD3 30 i^l of 10jxg/ml 0KT3 was added to 96-well round- 
bottom microtiter plates and incubated at 37°C for 90 minutes. The wells were 
washed with PBS three times and 2x10® cells added to each well in 0.2 ml 
media. Cells were incubated at 37°C and harvested at designated time points. 
For anti-CD28 stimulation of Jurkat lOpig/ml was used following the same 
procedure. Anti-CD28 antibody (clone CD28.2) was obtained from Pharmingen. 
For Cyclosporin inhibition experiments cells were treated with 200ng/ml CsA for 
the duration of induction with Doxycycline. Trypan blue staining was performed 
on CsA treated and non-treated Jurkat to exclude the possibility of toxicity prior to 
harvesting cells for RNA preparation. Drug inhibition assays used Cyclosporin 
obtained from Sigma and DRB obtained from Calbiochem.
2.10 RNA preparation
RNA was prepared using RNeasy extraction kits (Qiagen). Samples were DNase 
treated by incubation at 37° C for 30 minutes with DNase before cleaning using 
RNeasy spin columns. Samples were stored as ethanol precipitates at -70° C.
2.11 cDNA Synthesis
RNA (5^g in 5^1 DEPC water) was incubated with gene specific primers 
(Clontech) at 70°C for 2 minutes, then at 50°C for 2 minutes before addition of 
the reaction mix. This consisted of 5 mM deoxyribonucleotides (dNTPs), 0.1 M 
DTT (dithiothreitol, Melford Laboratories), Superscript Reverse Transcriptase 
buffer and finally Superscript Reverse Transcriptase (Gibco-BRL).
2.12 IVIicroarray Hybridisation
Gene specific primers were used to prime first strand cDNA synthesis. °^P- 
labelled cDNA probes were hybridised overnight to microarray membranes. After 
washing arrays were exposed to a phosphoimager screen for 24 hours.
2.13 cDNA Microarrays
The microarrays used were Atlas Human 1.2 Array, Atlas Human 1.2 Array II and 
Atlas Human 1.2 Array III from Clontech. These arrays represented a total of 
3528 genes. Controls include bacterial DNA, housekeeping genes and human 
genomic DNA. Arrays were made using gene specific primers to amplify 200- 
400-bp cDNA fragments that lack strong secondary structure. cDNA's were 
selected after sequence analysis to minimise cross hybridisation to other genes 
on the array. In addition selected cDNAs lack repetitive elements and poly-A 
sequences. Each individual microarray contained only 1,176 genes to maximise 
hybridisation sensitivity.
2.14 GenePix Pro 3.0 Data Analysis
Data was gathered from phosphoimager-scanned images using GenePix Pro 3.0 
software (Axon Instruments). Intensity values were obtained by first masking over 
array images. A grid containing a series of circles corresponding to the spots of 
the array was laid over the image, and the circles adjusted to each spot. The 
intensity of each pixel within the circle was calculated for each channel, termed 
"feature". For each raw image the mean, median and standard deviation of the 
pixel intensities in each feature indicator was computed. To reduce the effect of 
non-specific flourescence the background intensity was subtracted from the 
feature intensity before any ratio calculations were performed. A local 
background technique was used to subtract the background intensity. A different 
background was computed for each individual feature-indicator and the mean, 
median and standard deviation of the background pixel intensities were reported. 
For all ratio calculations that require background subtraction the median 
background is used. Various ratio quantities are computed by Genepix Pro 3.0 
allowing different appreciation of aspects of the raw data. These include ratios of 
overall derived feature properties, quantities derived from pixel-by-pixel ratios
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and quality factors such as the sum of medians, sum of means and log ratio-a 
base two logarithm of the ratio of medians.
2.15 Atlas Navigator Data Normalisation and Analysis
Before import to Atlas Navigator software the average of the median intensity 
values for each gene was calculated for at least three replicate experiments. In 
order to conduct comparisons between different experimental conditions average 
raw median intensity values were normalised at two levels. To eliminate 
differences due to varying exposure times I normalised each experiment to itself. 
By dividing the signal intensity of Gene A in Experiment 1 by the median signal 
intensity of all genes in experiment 1, the median of all measurements for each 
array was converted to 1. To eliminate the variation in intensity scale across 
different genes I normalised by comparing average raw median intensity values 
of all experiments to average raw median intensity values for non-treated control 
experiments. Here the signal intensity of gene A in experiment 1 was divided by 
the signal intensity of gene A in experiment X.
2.16 Cell lines
Cells were maintained in RPMI 1640 media (Gibco-BRL) with 10% tetracycline 
free fetal calf serum (Clontech) and penicillin/streptomycin (Gibco-BRL). For 
induction of transgene expression cells were treated with 1 |ig/ml doxycycline 
(Sigma). Cell lines Jurkat E6-1 and J.RT3 3 5.1 were obtained from American 
Type Tissue Collection (ATCC). pi 16 ZAP-70 and Syk negative Jurkat were 
kindly provided by Dr R. Abraham -  Duke University. Cell line Jurkat Tat III 
(Rosen et al., 1986) stably transfected with HIV III B Tat was obtained from the 
United Nations Programme of HIV/AIDS (UNAIDS) repository provided by Dr 
C.A. Rosen. All cell lines were tested routinely to confirm the absence of 
mycoplasma infection. Cells were incubated at 37°C, 5% CO2 and 100% humidity.
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2.17 DNA Transfections
DNA transfections were performed by electroporation of 5-10 million cells using a 
Biorad electroporator. Cells were resuspended with SOpig DNA in 0.4mls RPMI 
supplemented with PCS, penicillin and streptomycin and placed in 
electroporation cuvettes. Cells were electroporated using 950V, 72R 250 
capacitance. After electroporation cells were incubated in RPMI supplemented 
with PCS, penicillin and streptomycin as usual.
2.18 Luciferase assays
The HIV-1 LTR luciferase construct pBlue3’LTR-luc was obtained through the 
AIDS Research and Reference Reagent Program, Division of AIDS, National 
Institute of Allergy and Infectious Diseases, NIH from Dr. Reink Jeeninga and Dr. 
Ben Berkhout (Jeeninga et al., 2000). pLTR-luc, pRL-TK (Promega) and either 
PI2 or PI2-WT were electroporated into Jurkat III Tat cells. In all experiments 
transfections were performed in triplicate. Drug treatment with 10 or 20 fiM DRB 
was performed on a single pool of transfected cells. The Luciferase Assay 
system (Promega) was used to assay for luciferase activity at 36 hours post 
transfection. Transfection efficiency was normalised using the co-transfected 
Renilla luciferase activity.
2.19 Northern blots
Poly (A) RNA was prepared from Jurkat transfected with PI2-WT and control 
plasmids. RNA was electrophoresed through a 1% agarose formaldehyde gel 
and transferred to nylon membranes. [a-^^P] dCTP labelled cDNAs for CDK9 and 
|3-actin were prepared using Rediprime II from Amersham. Primer sequences 
used to prepare a 268bp CDK9 cDNA fragment are available from Clontech.
2.20 Lipid Raft Extraction
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Lipid raft fractions were purified by sucrose density gradient centrifugation. 50x 
10® cells were washed with cold PBS and lysed with lysis buffer containing 1% 
Triton X 100. Samples were cleared at 14,000g for 30 minutes before being 
overlayed with sucrose density gradient. This was composed of 1ml 85% sucrose 
in sucrose density gradient buffer, then 6mls 30% and finally 3.5mls of 0.5%. 
These were subjected to centrifugation at 34000g for 16 hours using a Beckman 
Ti40 rotor before 1ml fractions were harvested sequentially from each sample.
2.21 Immunoprécipitations
Immunoprécipitations were performed after lysis of cells with NP40 lysis buffer on 
ice for 30 minutes. Lysis buffer contained protease and phosphatase inhibitors. 
Samples were cleared at 14,000g for 15 minutes and subsequently precleared 
with either Protein A or Protein G (Sigma) for 1 hour at 4°C. Antibody was added 
and the sample rotated at 4°C for a further hour. Finally protein A or G was 
added before rotating for a final hour. Samples were pulse spun and the 
supernatant removed. Beads were boiled in SDS sample buffer for 5 minutes 
before loading on SDS PAGE gels.
2.22 Western Blots
For Nef western blots cells were lysed with NP40 lysis buffer and whole cell 
lysates electrophoresed on 12.5% SDS gels. Western blot was performed with 
anti-Nef antibody obtained from the UNAIDS repository supplied by Dr M. Harris. 
Anti-p-Actin antibody (clone A15) was obtained from Sigma.
2.23 CDK9 western blot and In vitro kinase assay
For CDK9 western blot and kinase assays cell lysates were prepared 36 hours 
post transfection with Nef or control expression plasmids. 1x 1 0^  cells were
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pelleted and washed in PBS at 4°C. Lysis buffer containing NP40 was added and 
cells left 5 minutes on ice. The lysate was spun and the pellet washed once with 
Tris buffer. Pellets were then disrupted by passing 10 times through a 26 gauge, 
0.375in injection needle and cleared at 14, 000 x g for 40 minutes. After 
electrophoresis on 12.5% SDS gels western blot was performed with anti-CDK9 
antibody (Santa Cruz). For in vitro kinase assays (IVKA) CDK9 was 
immunoprecipitated using anti-CDK9 antibody and kinase assays were 
performed as described by Herrmann et al., 1995. Beads were incubated for 30 
minutes at room temperature in kinase buffer in the presence and absence of 
CTD peptide as substrate. Proteins were blotted to nitrocellulose membranes 
after electrophoresis on tricene gels.
2.24 Primer Sequences for PGR Primers
Vector p-IRES-2-EGFP
Forward Primer GGA AGA TOT TOG AGG ATG GGT GGG AAG TGG
Reverse Primer TGG GGG GGG GGA TGA GGA GTG TTT GTA GTA
Vector PJEF
Forward Primer GGG GGA TGG GGG AGG ATG GGT GGG AAG TGG
TGA AAA GGT
Reverse Primer GGGGGA TGG GGG GGA GTG TTT GTA GTA ATA AGG 
Vector tet-on-IRES-EGFP
Forward Primer GGG GGA TGG GGG AGG ATG GGT GGG AAG TGG
TGA AAA GGT
Reverse Primer GGGGGA TGG GGG GGA GTG TTT GTA GTA ATA AGG 
HA-tagged Nef
Forward Primer GGG GGA TGG GGG AGG ATG GGT GGG AAG TGG
TGA AAA GGT
Reverse Primer GGG GGA TGG GGG AGG GTA GTG TGG GAG GTG
GTA TGG GTA GGA GTG TTT GTA GTA GTG GGG 
ATG
2.25 PCR Reaction Conditions
50pl Taq reaction
(Primers 0.2 jxM each, dNTPs 0.5mM, MgOb 2.5mM, V I Taq, 5^ 1 10x reaction 
buffer). 30 cycles: 95°C denaturing for 30 seconds, 60°C annealing for 30 
seconds and 72°C extension for 5 minutes. The annealing conditions varied from 
55°C to 68°C depending on each particular reaction set.
2.26 FACS Staining
Preparation of Celis for FACS Analysis
Cells were washed in cold PBS, counted and aliquoted between FACS tubes. 
They were further rinsed in FACS buffer before staining with appropriate 
antibodies and fixed with FACS fix solution.
Staining Reagents
Staining reagents were obtained from DAKO in the case of anti-CD4-RPE and 
W632-RPE. Anti-CD27-RPE antibody was obtained from Pharmingen. Samples 
were analysed by Becton-Dickenson FACScalibur or FACScan machines and 
CellQuest software.
2.27 Creation of Tetracycline Inducible cell lines
Tetracycline operator vector DNA was linearised at Bgl II. 16 reactions of 3fxg 
DNA were mixed in a linearisation reaction and gel purified. A 2^g reaction of a 
hygromycin resistance cassette (Clontech) was linearised at Hind III and gel 
purified. Both tetracycline vector and hygromycin cassette DNA were ethanol 
precipitated to give linearised DNA of tetracycline operator and selectable marker 
in a ratio of 24:1. Jurkat transactivator T cells obtained from (Clontech) had been 
split the previous day and were electroporated with the linearised DNA. After 24
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hours in culture in RPMI containing tetracycline free FBS, penicillin, streptonriycin 
and neomycin, hygromycin was added in a concentration of 200^g per ml. This 
resulted in widespread death of cells. After 2-3 weeks Hygromycin resistant 
Jurkat began to grow out. Single cell cloning of these cells was performed. After 
two weeks of growth in 96 well plates clones had grown sufficiently to be split into 
two and grown in 24 well plates. After a further week in culture with both 
neomycin and hygromycin one out of the two wells deriving from a single cell 
were subjected to induction with doxycycline at a concentration of Vg/ml. After 
24 hours these clones were analysed for EGFP expression by FACS. Clones 
demonstrating reasonable level of EGFP induction were then observed for 
evidence of background EGFP expression in the absence of doxycycline 
treatment.
2.27 2D gel Analysis
For whole cell lysates 24 hours post Nef expression 20 x 10® cells were lysed 
with NP40 lysis buffer. Lysates remained on ice for 30 minutes before 
centrifugation at 14,000g for 15 minutes. Acetone precipitation of the lysate was 
carried out and the resulting protein pellet resuspended in IPG rehydration buffer 
pH 3-10. pH gradient markers (Carbamylyte Calibration Kit, Pharmacia) were 
added. First dimension gels analysis was performed using 24cm IPGphor IPG 
strips pH 3-10 (Pharmacia). Gels were rehydrated for 12 hours, and isoelectric 
focusing was performed at 500V for 1 hour, followed by 1000V for 1 hour and 
8000V for 6 hours 30 minutes. After the lEF the IPG strips were equilibrated for 
15 minutes in buffer containing DTT and sealed over the second dimension gel 
using agarose. For the second dimension pre-cast 30cm 12.5% SDS gels were 
run at 15W until the focused proteins had run into the gel. Subsequently gels 
were run at 160W for 4 hours.
2.28 Silver Staining of 2D gels
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Gels were silver stained using Plus One silver staining kit from Pharmacia.
2.29 2D Gel Analysis
2D gels were scanned using UMAX Vista Scan and grayscale images analysed 
using the software package Melanie 3.0 (Genebio).
2.30 Gel excision and Mass Spectrometry
Selected protein slices/spots were excised, deposited in 96-well plates, in-gel 
reduced, alkylated with iodoacetamide and digested with trypsin as described 
(Schevchenko et al., 1996). The resulting peptides were digested with MALDI- 
MS and nanoES tandem MS. MALDI mass spectra were acquired automatically 
on a Bruker RE-FLEX III reflectron time of flight (TOF) mass spectrometer 
(Bruker Franzen, Bremen, Germany) as previously described (Vorm et al., 1994; 
Jensen et al., 1997). Peptides were analysed by nanoES tandem MS on a 
quadrupole time-of-flight mass spectrometer (QSTAR Pulsar, PE Sciex, Toronto, 
Canada) equipped with a nanoES ion source (MDS-Proteomics, Denmark). The 
peptide mixtures from in gel digests were purified and concentrated prior to 
nanoESMS as described (Wilm et al., 1996), except that the remaining 
supernatant were loaded on columns in parallel from 96-well plates.
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Chapter 3
The Nef CD4 T cell Gene Expression Profile
3.1 Introduction
In order to probe a molecular basis for the function of Nef in alteration of T cell 
signalling I undertook large scale gene expression profiling analysis screening for 
expression changes in 3528 known genes. I reasoned any effect of Nef on T cell 
signal transduction paths should manifest itself in differential gene regulation with 
the potential to affect the viral life cycle. In order to undertake such an analysis it 
was necessary to develop a system that allowed tight temporal control of Nef 
expression. HIV is a cytopathic virus. Except in the case of post-integration 
latency the time from viral entry to virion production and cytopathicity has been 
estimated to be around 24-48 hours. Therefore it was appropriate to attempt to 
document gene expression changes at early time points after Nef expression in T 
cells.
3.2 The tetracycline inducible system
The study of gene function in complex cellular environments requires systems 
that allow stringent control of the expression of individual genes. The aim of such 
a system is not only to provide temporal control but regulated control of the level 
of gene expression. Several systems are available for inducible control of gene 
expression. These include use of promoters responsive to heavy metal ions 
(Mayo et al., 1982, Brinster et al., 1982, Searle et al., 1985), heat shock (Nouer 
et al., 1991), or hormones (Lee et al., 1981, Hynes et al., 1981, KIock et al., 
1987, Israel et al., 1989). Ail of these systems have suffered from leakiness of 
the inactive state. In addition results are affected by the pleiotropic effect of the
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inducing agent (Lee et al., 1988) making them less than ideal candidates for 
studies of gene expression.
Bujard and Gossen described an inducible system based on the regulatory 
elements of the TnfO-specified tetracycline-resistance operon of E.co//(Hilien et 
al., 1989). Transcription of resistance mediating genes in this system is 
negatively regulated by the tetracycline repressor (tetR). In the presence of 
tetracycline tetR does not bind to its operator sequences in the operon promoter 
and transcription is facilitated. Bujard and Gossen combined the tetR with the C- 
terminal domain of VP16 from HSV. VP16 is essential for HSV immediate early 
gene (lEG) transcription. This chimera stimulates minimal promoters bound to 
tetracycline operator sequences. In the presence of tetracycline the tetracycline 
transactivator (tTA) is prevented from binding to tetO sequences. The 
tetracycline system has subsequently been modified by a single amino acid 
change in the tetracycline transactivator such that it will only bind the operator 
sequences in the presence of tetracycline. This modification is of use in the 
context of animal experiments preventing complications and costs of prolonged 
periods of tetracycline treatment. More generally the modification is of benefit as 
it allows tighter temporal control of gene induction. This is because transcription 
of the transgene is not dependant on the half-life of disappearance of tetracycline 
from plasma or tissue culture media.
3.3 Generation of Nef expression constructs
A panel of nef expression constructs was created. Tetracycline operator 
constructs containing nef or nef mutants were made. These constructs were of 
three varieties: containing nef alone, nef bicistronic for EGFP, and nef C-terminal 
EGFP fusions. Tetracycline operator constructs containing nef alone were made 
by cloning nef into the vector pJEF4 obtained from Manfred Gossen (Figure 3a) 
IRES-EGFP tetracycline operator vectors were made by cloning the tetracycline 
operator sequences from pJEF4 and inserting them upstream of the MCS in p- 
IRES-EGFP from Clontech. Wild type (WT) nef was cloned from HIV SF2
backbone expression construct (Sanchez-Pescador et ai., 1986). Mutant vectors 
contained nef mutated in the SH3 binding domain (P76A), in a motif implicated in
Fiq 3a Schematic representation of nef expression constructs. EGFP Is represented bv a 
qieen diamond, iPES  hv a filled rectangle arni.ncf tf-/ an enr^y rectangle The .'lef mutant 02A  
contains an alanine tor glyCine substitution .«t position 2 This destn>,-s nryristovlalion of In 
P76A. an afanme for proline substaution at position 76 oi the SH3 bind in g domain is present 
RR consists of a di I eu cine subsincsion for di arginine at positions 109 and 110, This liisrupts the 
Nef P.ÂK kinase association. EDa.a contains a di a la nine saiO-stitution at amino acids 178 and 
179 disrupting a motif Implicated i i  CD4 dovmregulation. In Tetracycline expression vectors 
these inserts are expressed from  the Tet response element (TRE). Othen/v-ise the/ are 
expressed under control of the CMV promoter.
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CD4 downregulation (EDAA) and in the di-arginine domain mediating association 
with PAK kinase (RR). in addition to the tetracycline operator vectors a panel of 
vectors for conventional expression of nef in transient transfection were made. 
These consisted of nef and mutant nefs being inserted in the vector plRES-2- 
EGFP from Clontech. Inserts were sequenced and expression tested after 
transient transfection into tetracycline transactivator Jurkat obtained from 
Clontech. After treatment with doxycycline for 24-48 hours cells were harvested 
and FACS analysis performed in the case of constructs containing EGFP. In
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addition the expression of the nef insert in each vector was confirmed by western 
blot.
3.4 Generation of Double Stable tetracycline inducible cell lines
A detailed account of the construction of tetracycline inducible cell lines is 
provided in materials and methods. DNA constructs were linearised before 
transfection by electroporation and selection in neomycin and hygromycin. 
Between 14 and 21 days hygromycin resistant cells were detectable and single 
cell cloning was commenced. At 14 days clones were split and one half were 
induced with doxycycline in preparation for screening for EGFP expression by 
FACS analysis. Clones exhibiting EGFP fluorescence were tested for little or
Fig 3b. Western blot analysis of cell lines inducibly expressing WT-EGFP 
and control EGFP alone showing induction of Nef at 12, 24 and 48 hours 
after addition of doxycycline at V g /rrl (top panel). The membranes are 
stripped and blotted for |3-Actin (bottom panel).
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Fig 3c. FACS analysis of EGFP expression pre and post treatment of WT- 
EGFP and control cell lines with doxycycline illustrating tightly regulated 
EGFP expression in Nef positive and control cells.
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negative background expression. Those that fulfilled these criteria were tested for 
Nef expression after doxycycline induction by Western blot (Figure 3b). In 
selected clones Western blot and FACS analysis showed tightly regulated gene 
expression pre and post treatment with doxycycline (Figure 3c). Growth of the 
WT-EGFP cell line in doxycycline resulted in a decrease in CD4 and MHC class 
1 expression consistent with previous reports (Greenberg et al., 1998) (Fig 3d). A 
control cell line was generated that expressed EGFP alone after doxycycline 
induction.
3.5 Loss of expression in the tetracycline inducible system
An unfortunate feature of all of the tetracycline cell lines generated was an 
irreversible loss of inducibility and loss of expression after more than six weeks in 
culture. This could have been due to several causes. In the case of Nef 
tetracycline cell lines as Nef is toxic and causes apoptosis after prolonged 
expression in T cells any leakiness of the inducible system would result in 
gradual apoptosis of Nef expressing cells favouring the outgrowth of Jurkat 
where the insert was silenced. However most of the established clones did not 
demonstrate background EGFP fluorescence.
Loss of expression is a commonly documented flaw of the tetracycline inducible 
system. This has been reported to be due to méthylation of the promotor in the
Fig 3d. FACS dot plots after dual staining of non-induced and doxycycline 
induced populations with MHC 1 PE and CD4 TRI. Nef positive cells 
down regulate MHC 1 and CD4 as expected.
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case of a tetracycline inducible BRCA1 cell line (Harkin et al., 1999). In this case 
the loss of inducibility after withdrawal of doxycycline was reversible after 
treatment of the Hela cells with the demethylating agent cytidine. Nef tetracycline 
cells in which Nef expression had become undetectable after induction with 
doxycycline were tested for hypermethylation of the promoter by treatment with 
cytidine. No reversal of inhibition was observed. Another known cause of gene 
silencing is hypoacetylation of histones surrounding promoter elements. This can 
be reversed by hyperacetylation that may be induced by treatment with butyrate. 
However treatment of Nef tetracycline cells with butyrate did not result in a 
reversal of silencing after treatment with doxycycline.
Loss of expression was not dependant on the particular Nef insert or indeed 
entirely due to Nef as control EGFP tetracycline cells also demonstrated failure of 
induction after passage in culture. I established by transient transfection of 
tetracycline transactivator Jurkat from Clontech that between eight and twelve 
weeks in culture the cells were no longer responsive to doxycycline and the cells 
therefore had lost expression of the transactivator element. Loss of expression of 
the rtTA is likely to be a major contributor to the lack of longevity of established 
tetracycline inducible cell lines in this instance.
3.6 Screening of cDNA microarrays
I screened for differential changes in gene expression occurring over time after 
induction of Nef in tetracycline inducible cell lines. As an early expressed HIV 
gene any host cell transcriptional changes exerted by Nef are likely to have 
relevance for the viral life cycle at earlier time points. Expression profiles at 18, 
24, 30 and 36 hours after doxycycline treatment were compared. As Nef is first 
detectable at 12 hours in the cell lines this is representative of 6, 12, 18 and 24 
hours after Nef expression. Total RNA was used to make pP ] cDNA probes. 
Using Clontech cDNA microarrays 3528 genes were analysed. Raw intensity 
values were obtained from at least three replicate experiments using GenePix
3.0 (Axon Instruments) software. Atlas Navigator (Clontech/ Sigenetics) software
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was used for subsequent normalisation and cluster analysis. Full experimental 
details describing microarray methods and analysis are found in materials and 
methods. Nef produces widespread differential gene expression in the T cell that 
escalates in breadth and intensity over time. In contrast doxycyline treatment of 
control EGFP expressing cell lines resulted in no significant changes in gene 
induction (Fig 3e).
3.7 The Nef T cell gene expression profile
An initial analysis focused on up regulated genes as these are the most 
commonly described targets of signal transduction cascades. We defined 
significantly upregulated genes as exhibiting a normalised relative intensity ratio 
of three or above, with a raw intensity value more than 150. A complete list of 
genes upregulated by Nef over 24 hours is available in the Appendix. K-tuple 
means clustering (Eisen et al., 1998) was used to display the kinetics of Nef 
induced gene expression. Using the standard correlation coefficient genes 
clustered into two nodes of upregulated transcripts (Figure 3f). Cluster group A 
contains genes whose expression is gradually induced over the time course and 
whose expression peaks towards later time points. Cluster group B contains 
genes whose expression achieves a plateau at earlier time points. A relative over 
representation of transcription factors, RNA processing genes and genes 
directing post-translational modification is observed in cluster group A. Cluster 
group B contains intracellular transducers, genes regulating protein turnover and 
metabolic regulators. Genes on the arrays that were previously demonstrated as 
induced by Nef included MIP-ip and MIP-1a (Swingler et al., 1999) and these 
were upregulated as expected.
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Fig 3e. Serial scatter profiles 
demonstrate gene expression 
over time after induction of Nef 
Raw intensity values are plotted 
against control values for each 
gene (see normalisation 
methods. materials and 
methods). The green lines 
indicate the relative expression 
of the data sets relative to time 
0 The upper line marks a two­
fold increase, the lower line 
marks a two-fold decrease and 
the centre line indicates 
equivalent expression. The 
colour scale indicates relative 
up and downregulation of genes 
with red representing up and 
purple down regu I cation The 
intensity of the colour gives a 
indication as to the significance 
of the change in gene 
expression with high intensity 
correlating with more significant 
changes
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Fig 3f. K-tuple clustering was used to display the expression ratios of 
Nef induced genes over time. Included in the cluster ana^sis were 
genes that are upregulated more than three in normalised relative 
intensity ratio of signal to control. All measurements are relative to time 
0. The colour scale ranges from saturated red for up-regulated genes to 
saturated blue for down-regulated genes according to the key. A single 
row of coloured boxes represents each gene and each column a single 
time point. Significantly induced (raw intensity more than 150) functional 
groups of co-regulated genes are indicated.
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3.8 Nef induces positive regulators of virai replication
A series of genes impacting on the viral life cycle are upregulated by Nef (Table 
3.1). Strikingly fifteen transcription factors that activate the HIV-1 LTR are 
induced. Cellular host proteins bind to a variety of cis acting DNA sequences 
located within the LTR and tightly regulate HIV-1 proviral gene expression. 
Multiple regulatory regions are required for LTR transactivation. Mutations in the 
SP1, TATA, TAR loop and stem secondary structure severly disable the 
response of LTR reporters to exogenous activators. Nef induces ETS-1, which 
acts co-operatively with NF-kB and NFAT to mediate synergistic activation of the 
HIV-1 and HIV-2 enhancers (Bassuk et al., 1997). ETS-1 also acts synergistically 
with USF-1 at the HIV distal enhancer region of the LTR (Sieweke et al., 1998). 
ATF-2 induces HIV transcription and increased levels of ATF proteins and DNA 
binding activity are observed in nuclear extracts of T cell lines infected with HIV 
(Rabbi et al., 1997). GAPB alpha activates the LTR in a Rafi responsive manner 
(Flory et al., 1996). IRF-1 and IRF-2 bind to the downstream binding factor site in 
the HIV promoter to exert a positive effect on viral replication (Van Lint et al., 
1997). In addition IRF-2 inhibits virus induced IFN-|3 transcription by preventing 
enhanceosome-dependant recruitment of the CBP-Pol II holoenzyme complex 
(Senger et al., 2000). Several of the HIV LTR transactivators Nef up regulates 
(NFATc, c-fos, JunD, IRF-1, c-myb, CIITA and HIV-EP2) are inducibly expressed 
on T cell activation. (Chupvila et al., Bosselut et al., 1992, Dasgupta et al., 1990, 
Kinoshita et al., 1997, Mercier et al., 1994, Saifuddin et al., 2000).
It was interesting to observe upregulation of several host cell factors required 
for action of another viral accessory gene product. Tat. One of these, CDK9, is 
the catalytic component of transcription elongation factor b (P-TEFb) that acts in 
concert with Tat to direct the processivity of HIV transcription (Zhu et al., 1997; 
Mancebo et al., 1997). CDK9 mRNA and protein levels are induced following T 
cell activation and this correlates with kinase activity (Herrmann et al., 1998). In 
addition to upregulating CDK9 Nef may prevent its degradation by induction of 
heat-shock protein 70 (Hsp70). Hsp70 serves as a chaperone that stabilises
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CDK9 prior to binding by a cyclin partner (O'Keeffe et al., 2000). Hsp70 is known 
to be induced following HIV infection of CD4 T cell lines and this induction is 
coincident with the presence of singly and multiply spliced HIV-1 transcripts, 
declining on the emergence of full-length genomic HIV-1 mRNA (Wainberg et al., 
1997). Nef induces several other genes that positively regulate Tat. These 
include Tat-SFI whose over-expression specifically stimulates transcriptional
Table 3.1 Nef upregulated genes associated with HIV
Transcription Factors Positively regulating the HIV-1 LTR
Encoded Protein
GenBank
Accession
number
Maximal 
normalised 
relative 
intensity ratio
Pur-alpha M96684 8.0
NFATc U08015 5.1
NF-KB p i00; p52 X61498 3.3
IRF2 X I5949 4.6
IRF1 X I4454 4.0
c-myb M l5024 14.4
c-fos K00650 3.5
Jun-D X56681 3.2
ETS-1 J04101 4.0
ATF-2 L05515 3.4
CIITA X74301 4.1
HIV-EP2 M60119 4.6
GABP-alpha D13316 4.4
TFIID 28KD subunit X83928 7.9
Tat facilitators required for processivity of transcription
TAR binding protein M60801 3.0
RNA pol II (RPB 3) J05448 3.9
RNA pol II (RPB 2) X63563 4.8
RNA pol II (RPB 6) Z27113 3.1
CDK9 L25676 10.7
TAT-SFI U76992 3.3
c-abi M l4752 7.3
Formation of full length transcripts
U1 SNRNP A protein X06347 5.0
Nuclear pore transporter
N UP-98 U41815 15.6
Increased in HIV PBMC
70Kd HSP 1 M11717 4.8
Heat shock related 70kd protein 2 L26336 10.1
IL6 receptor beta subunit M57230 6.7
Paracrine effectors
IL4 precursor Ml 3982 4.8
MIP-1 alpha M23452 9.9
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MIP-1 beta J04130 3.2
TGF beta X02812 3.4
Incorporation in virions
ezrin X51521 4.1
activity of Tat in vivo (Kim et al., 1999); TAR binding protein (TRBP) which acts in 
synergy with Tat to activate the LTR (Gatignol et al., 1996) and Pur a, a single 
strand DNA binding protein that binds TAR RNA and activates HIV transcription 
(Chepenik et al., 1998). In addition Nef upregulates c-abI tyrosine kinase that 
phosphorylates the carboxy terminal domain (CTD) of RNA polymerase II 
activating the HIV promoter in the absence of Tat (Baskaran et al., 1999). 
Upregulation otU1 SNRNP is observed. U1 SNRNP maintains inactivity of the 5'
LTR poly (A) site required for the formation of mature HIV transcripts by 
interaction with the major splice donor site (Ashe et al., 1997).
Nef induces several paracrine effectors over 24 hours (Table 3.1). 
Apart from MiP-1a and MIP-1 p two have been described as influencing the HIV 
life cycle. TGF-p is increased in the supernatants of HIV infected peripheral blood 
mononuclear cell (PBMC) cultures (Kekow et al., 1990) and is capable of 
stimulating transcription from the LTR by activating NF-kB (Li et al., 1998). IL4 
stimulates the expression of all HIV isolates via a transcriptional activation 
mechanism (Valentin et al., 1998). Altogether the expression profile hints Nef 
acts to further the viral life cycle by directing the accessibility of multiple CD4 T 
cell factors via an intrinsic activation trigger.
3.9 Nef down regulates various T cell genes
Nef differentially regulates expression of multiple genes in T cells. Less is known 
about the effect of signal transduction pathways on the downregulation of T cell 
transcripts. Atlas navigator software gives normalised raw intensity values of 
between 0 and 1 for down regulated genes. I defined down regulated genes as 
exhibiting a normalised relative expression value of less than or equal to 0.3. By 
these criteria 131 genes were down regulated. Of note Nef downregulates both
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Fig 3g. Nef down regulates 131 genes less than 0.3 in normalised 
relative intensity ratio over 24 hours. This ordered list taken from array 
NG 1 2 III IS representative of all three arrays The most downregulated 
genes are represented as saturated blue according to the key Each row 
represents a single gene and each column time points after induction of 
Nef from ne.ftet T cell lines
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CD27 and CD27 ligand which are conventionally induced on T cell activation and 
which are believed to play a role in T cell proliferation. Interferon gamma and 
interferon gamma receptor are downregulated that may mediate evasion from the 
immune response. In addition interferon beta shows downregulation in the 
presence of Nef. Proteosome components involved in antigen presentation are 
downregulated as is another immune mediator macrophage stimulating protein. 
Interestingly several positive effectors were downregulated including the kinases 
ZAP-70 and PKC-s, the phospholipase PLC-y2 and the 40S Ribosomal protein 
(Figure 3g). A complete list of genes downregulated by Nef over 24 hours is 
available in the Appendix.
3.10 Immediate early genes induced by Nef
As any Nef mediated alteration of the host CD4 T cell transcriptional environment 
is likely to have relevance for viral replication very early in the life cycle I 
attempted to define immediate early gene (lEG) expression induced by Nef. 
Changes to the cellular environment result in expression of a characteristic set of 
genes known as immediate early genes (lEGs). These rapidly activated genes 
have been have been observed to be identical whether induced after activation 
through multiple growth factors. Distinct signalling pathways triggered from the 
same receptor lead to upregulation of the same pattern of immediate early genes 
(Fambrough et al. 1999). These genes include c-fos and c-Jun, two components 
of the transcription factor AP-1 involved in activating gene expression from a 
variety of genes involved in growth and differentiation (Foletta et al. 1998; 
Shaulian and Karin 2001). Other lEGs include HSP70 which aids in protein 
folding and heat shock responses, CPBP a transcription factor that enhances 
transcription from TATA-less promoters, MKP-1 a phosphatase that 
dephosphorylates MAP kinases; and TTP which binds certain mRNAs and 
promotes their degradation.
A hurdle in performing this analysis involved definition of the time point after Nef 
induction in the Nef tetracycline cells that represents a period where lEG
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induction might occur. EGFP expression is observed at 18 hours after 
doxycycline treatment at the earliest. Nef tetracycline cells were harvested for 
RNA generation after 19 hours treatment with doxycycline. Microarray analysis 
was performed as described previously. Due to the difficulties in definition of the 
time period of true I EG induction in this system the results must be interpreted 
with caution.
Induction of several genes classically described as lEGs was observed. In 
addition several genes were induced that are not upregulated at later time points 
in the Nef expression profile. The functional logic that links these lEGs is not 
known.
3.11 The Nef expression profile as an indicator of specific functions
The potential for individual genes differentially regulated by Nef to exert effects 
on viral replication was examined. Nef mediated induction of CDK9 mRNA was 
observed in the cDNA microarray analysis. CDK9 is a key component of the 
positive elongation factor complex (P-TEFb) that acts in concert with Tat to 
facilitate processive transcription by phosphorylating the C-terminal domain 
(CTD) of RNA polymerase II. Nuclear extracts depleted of CDK9 lose ability to 
stimulate processive transcription (Mancebo et al., 1997; Zhu et al., 1997). In 
addition the purine nucleoside analogue 5, 6-dichloro-1-(3- D - 
ribofuranosylbenzimidazole (DRB) that specifically inhibits CDK9 can effectively 
terminate Tat transcriptional activity (Marciniak and Sharp, 1991, Zhou et al., 
2000). CDK9 mRNA and CDK9 catalytic activity is induced in activated primary T 
lymphocytes (Yang et al., 1997; Hermann et al., 1998). Nef expression in Jurkat 
was found to induce CDK9 protein (Fig Si) and kinase activity (Fig 3j) in addition 
to mRNA (Fig 3h). The effect of Nef mediated CDK9 upregulation on the 
efficiency of HIV-1 transcription directed by Tat was investigated. Jurkat stably 
transfected with Tat were transiently transfected with either an HIV-1 LTR 
luciferase reporter or HIV-1 LTR luciferase and Nef. HIV-1 LTR activity in the 
presence of Nef and Tat was hyperinduced in comparison with activity observed
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in the presence of Tat alone (Fig 3k). To establish the contribution of Nef 
mediated induction of CDK9 to this effect co-transfected cells were treated with 
10 or 20 riM DRB which resulted in a dose dependent reduction in LTR luciferase 
activity. Induction of CDK9 may be a significant aspect of the mechanism by 
which Nef enhances viral production.
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3.12 Discussion
As the earliest expressed gene of HIV the ability of Nef to influence host cell 
gene expression is tantalising as it has implications for HIV replicative fate. 
Several of the genes Nef induces have previously been identified as influencing 
events in the viral life cycle. In addition 26 of the genes induced more than three 
fold in normalised relative expression ratio have been described as being 
upregulated after T cell activation. It is possible different variants of Nef may 
differ in their ability to induce or repress expression of host cell factors influencing 
HIV replication. In this way Nef might exert some control of level of HIV disease 
progression. The ability of Nef to induce a transcriptional program in T cells 
indicates that the described in vitro interactions with key T cell signalling proteins 
may lead to a functional outcome in vivo. As there is currently no drug inhibitor of 
Nef action delineation of the protein-protein interaction that leads to T cell gene 
expression changes will be important if this function of Nef is to be targeted 
therapeutically.
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Chapter 4
Characterisation of the Nef CD4 T Cell 
Transcriptional Programme
4.1 Introduction
Within the Nef expression profile upregulation of 23 genes that are also induced 
on T cell activation was observed. These included ETS-1, CDC2, CDK9, ezrin, 
Jun-D, c-abl, CDK4, c-fos, c-myb, NF-kB p100; p52, GAPB-alpha, NFATc, PUR 
alpha, MIP 1-beta, Heat shock related 70kd protein 2, 70kd MSP 1, TGF beta, 
MIP 1-alpha, IL4 precursor, HIV-EP2, GUTA, NUP-98, beta’-COP, RNA pol II- 
(RP3), (RPB2) and (RPB6), TAFII-28, TATSF1, U1 SNRNP A and TAR binding 
protein. Previous assessnnents of activation of T cells by Nef have utilised 
readouts obtained from NF-kB, NFAT, AP1 and IL2 reporter constructs, 
measurements of calcium flux, changes in tyrosine phosphorylation or in vitro 
kinase assays assessing catalytic activity of key T cell signaling molecules. While 
giving insight to the effect of Nef on T cell activation paths in specific 
experimental contexts, they do not provide a unifying picture as to extent or 
specificity of Nef T cell activation. Indeed some studies have inferred a inhibitory 
effect of Nef on T cell signaling (Bandres and Ratner, 1994, Collette et al., 1996, 
Greenway et al., 1996, lafrate et al., 1997). Large scale gene expression profiling 
enables comparison of the Nef profile to reference activation states. I attempted 
to compare the expression profiles obtained after Nef expression in GD4 T cells 
with that occurring after either anti-CD3 or anti-CD28 activation.
4.2 Comparison of the Nef gene expression profile with that of reference T 
cell activation states
ftn
I activated Jurkat with plate bound anti-CD3 and performed cDNA microarray 
analysis at 12 and 24 hours. These profiles were compared to those obtained 
after Nef induction at 24 and 36 hours in the tetracycline inducible cell lines 
(representative of 12 and 24 hours from when Nef is detectable). Ligation of CD3 
induces a transcriptional program of similar magnitude to that of Nef (Figure 4a).
While T cell activation by TCR triggering and Nef expression induce a number of
shared genes that promote the virus life cycle some potentially important 
differences were noted. Ten transcripts absent from the anti-CD3 activation 
profile are upregulated by Nef (Table 4.1). Three of these genes TAT-SF1, IRF-2 
and U1 SNRNP are positive regulators of the viral life cycle. IRF-2 prevents virus
Remarkably the activation of Jurkat via this route revealed 97% identity (p<0.01) 
in upregulated transcripts with those of Nef (Figure 4b). In contrast activation of 
Jurkat via plate bound anti-CD28 results in induction of 145 genes over 24 hours 
with 80% identity in induced genes (Fig 4b). A full list of CD28 induced genes is 
provided in the Appendix. The entire Nef expression profile including 
downregulated and equivalently regulated genes demonstrates a high degree of 
similarity with that of anti-CD3 triggering as demonstrated in Figure 4c.
While T cell activation by TCR triggering and Nef expression induce a number of 
shared genes that promote the virus life cycle some potentially important 
differences were noted. Ten transcripts absent from the anti-CD3 activation 
profile are upregulated by Nef (Table 4.1). Three of these genes TAT-SF1, IRF-2 
and U1 SNRNP are positive regulators of the viral life cycle. IRF-2 prevents virus
induced IFN-p gene transcription (Senger et al., 2000). Anti-CD3 activation 
resulted in upregulation of 8 transcripts absent from the Nef profile (Table 3.1). 
These include the transcription factor YY1 that represses HIV-1 LTR activity 
(Coull et al., 2000) and cytokine IL16 that inhibits HIV growth in cell culture 
(Center et al., 2000). I examined whether the differences observed in mRNA 
level correlated with expression changes in protein for several of these genes. It
Figure 4a. The Nef expression profile compared with that of anti-CD3 
activation. Scatter plots show equivalent induction of differential gene 
expression between Nef activated and anti-CD3 activated T cells. The 
colour key indicates upregdated genes as sauturated red and 
downregulated genes as saturated blue.
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Figure 4b. Ordered list representation of genes upregulated more than 3 in normalised 
relative intensity value from array HG 1.III. This is representative of all three arrays used. 
Upregulated genes show a similar expression pattern both in kinetics and magnitude of 
induction after Nef expression or anti-CD3 stimulation. In contrast anti-CD28 stimulation 
shows less similarity. The colour key indicates upregulated genes as saturated red. Each 
row represents a single gene and each column time points after induction of Nef, or after 
stimulation with anti-CD3 or anti-CD28.
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Figure 4c. The kinetics and magnitude of the Nef and anti-CD3 expression 
profiles are similar for up and downregulated genes.
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Table 4.1 Differences between the Nef and anti-CD3 expression profiles 
and how these are preserved after exogenous stimulation
Encoded Protein GenBank
Accession
number
Maximal
normalised relative
intensity
ratio
Genes upregulated by Nef but not anti-CD3
IRF-2 X15949 4.6
Tat SF1 U76992 3.4
U1 SNRNPA X06347 5.0
P'-COP X70476 3.9
DPI L23959 4.0
Pinch protein U09284 9.0
PLC-p 3 Z16411 4.0
Genes upregulated by anti-CD3 but not Nef
IL16 M90391 17.1
YY1 M76541 5.8
CD27 M26842 5.9
NF-X1 U15306 3.3
MTA1 like 1 AB016591 6.2
ALARS D32050 4.0
Mitochondrial Lon protease 
homolog precursor
X74215 21.3
hTRF2 AF002999 3.1
Normalised intensity ratios for HIV associated genes after CD3/CD28 stimulation
Encoded Protein GenBank
Accession
number
Maximal
normalised relative
intensity
ratio
(CD3/CD28)
Maximal
normalised relative
intensity
ratio
(Nef and
CD3/CD28)
IRF-2 X15949 2.3 8.4
Tat SF1 U76992 1.4 6.3
U1 SNRNPA X06347 2.8 7.4
IL16 M90391 17.4 1.1
YY1 M76541 5.2 2.3
CD27 M26842 6.3 2.9
was possible to demonstrate a difference in protein expression for the 
transcripion factor IRF-2 (Figure 4dii). CD27 is exclusively induced by CDS 
crosslinking of Jurkat but not by Nef. This was demonstrated by FACS analysis 
of anti-CD3 activated T cells transfected with a control EGFP expression vector 
in comparison with Jurkat transfected with plRES2-WT-EGFP (Figure 4di). These 
differences hint the mode of Nef T cell activation may be highly specific and 
geared towards a heightened replicative state for the virus over and above a 
conventional activation stimulus.
Fig 4d. Differences between Nef and anti-CD3 expression profiles 
indicate that Nef may activate T cells in a manner specifically 
geared to promote viral replication. These changes in mRNA levels 
may not be indicative of changes in protein expression.
(i) CD27 surface expression on Nef transfected and anti-CD3 
activated Jurkat. Expresson of WT Nef does not correlate with a 
change in CD27 expressbn on the cell surface in contrast to anti- 
CD3 stimulation which resUts in marked induction of cell surface 
anti-CD27.
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(ii) Comparison between IRF-2 expression levels in Nef transfected 
And anti-CD3 activated Jurkat. Western blot of IRF-2 expression 
in nuclear lysates of Nef expressing Jurkat and anti-CD3 
activated Jurkat.
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4.3 Effect of Exogenous activation on the Nef expression profile
I examined how this single signal T cell activation triggered by Nef might present 
an advantage to viral replication following subsequent exogenous activation. This 
single signal activation by CDS triggering is weak and may represent more of a 
priming role. Alternatively it may facilitate induction of anergy and postintegration 
latency by representing a first single trigger that renders the host T cell resistant 
to further stimuli. The expression profile of Jurkat activated through CDS and 
CD28 was compared to that of Nef expressing Jurkat activated via this route. 
Genes induced after CD3/CD28 activation represent a combination of the 
transcripts induced after activation via either route singly. The presence of Nef 
results in hyperinduction of several T cell inducible genes including IL2 and 
NFATc. In addition the differences observed between the anti-CD3 and Nef 
profiles are preserved (Table 4.1). CD3/CD28 stimulation results in upregulation 
of interferon ap receptor that does not occur in the presence of Nef. IL3 
precursor is induced exclusively in the presence of Nef. Genes induced after 
combined CD3/CD28 stimulation of Nef expressing cells are listed in the 
Appendix.
4.4 Nef acts above the level of calcineurin
It follows from the close identity between Nef and anti-CD3 expression profiles 
that formation of the Nef transcriptome should occur via the same signalling and 
transcriptional constraints as govern anti-CD3 T cell activation. To establish to 
what extent the NFAT/NF-k B family of transcription factors participates in 
formation of the Nef profile Nef tetracycline cell lines were treated with 
Cyclosporin A (CsA) during the period of induction with doxycycline. The 
concentration of CsA used was within the range maintained in the blood of liver 
transplant recipients receiving CsA. Trypan blue staining revealed no evidence of 
toxicity at this dose of CsA. The expression profiles obtained at 36 hours post 
induction (representative of 24 hours post Nef expression) were compared. CsA
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treatment led to a marked suppression of the Nef expression profile (Figure 4e 
and Figure 4f). In the presence of CsA only 49% of Nef induced genes were 
upregulated. CsA inhibits induction of CIITA (Charreau et al., 2000) and this was 
inhibited in our analysis. CsA does not affect T cell activation upregulation of 
CDK4 (Modiano et al., 1994) and this was induced as expected. No new genes 
were upregulated following CsA treatment of Nef expressing cells. Full 
documentation of the effect of CsA on Nef induced genes is provided in the 
Appendix. The in vitro growth advantage of Nef positive HIV virus can be 
inhibited by cyclosporin (Aiken, C. 1998). It was interesting to note CsA inhibited 
the Nef mediated induction of several factors that could enhance viral 
productivity. These included CDK9, Tat-SF1, NFATc, NF-kB, IRF-2, c-abi, ATF- 
2, CIITA and GAPB-alpha. The 49% gene repression occuring in the presence of 
CsA indicates a substantial portion of Nef T cell signalling is transmitted via the 
NFAT/NF-KB family and that Nef orchestrates formation of the expression profile 
above calcineurin in the T cell signalling path.
RR
Figure 4e. The Nef expression profile is suppressed by CsA. Nef tet cell lines 
were treated with cyclosporin at 200ng/ml and were induced with doxycycline. 
The scoter plots de men state a general repression in gene inducton 
occurring at 36 hours after CsA trealmert. The colour key indicées 
upregulated genes are represented as saturated red and downregulated 
genes as saturated blue.
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Fig 4f. Nef tet cell lines were treated with cyclosporin at 200ng/ml and were 
induced with doxycycline. The ordered list indicates genes unaffected in 
induction or partially and completely inhibited in induction in the presence 
of CsA. Genes were defined as unaffected by CsA if their expressicn ratio 
differs by less than 30% from the ratio obtained in untreated cells. Genes 
whose expression ratio is reduced by more than 70% are defined as fully 
repressed and genes whose expression ratio is decreased by less than 
30% but more than 70% are defined as partially repressed. The colour key 
indicates upregulated genes as saturated red and downregualted genes as 
saturated blue.
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4.5 Use of genetic T cell signalling mutants to locate position of Nef action
We elected to use the hallmark Nef expression profile to investigate the role of 
key T cell signalling molecules in its induction. Nef can interact with a number of 
these and in addition is associated with accumulation of others in lipid rafts. The 
most proximal T cell signalling Nef binding protein described is TCR^. In order to 
define the exact position where Nef might act we compared gene profiles 
obtained when Nef was expressed in cell lines lacking functional TCRÇ (J RT3- 
T3.5 Ohashi et al., 1985) and genetically deficient in ZAP-70 (pi 16). Nef tet 
inducible J RT3-T3.5 and pi 16 cell lines were constructed by co-transfection of 
tet transactivator and operator plasmids containing nef. Stable cell lines were 
selected on the basis of high inducible expression with minimal background leak 
(Figure 4g). Induction of Nef expression in both J RT3-T3.5 and pi 16 resulted in 
an attenuation of Nefs transcriptional response which was most marked in cell 
line J RT3-T3.5 (Figure 4h and Figure 4i). We analysed the transcripts 
upregulated more than 3 fold in each cell line. Absence of TCR^ resulted in a 
loss of 52% of Nef induced genes while in the absence of ZAP-70 44% of Nef 
induced genes were not upregulated. (The Appendix contains gene lists of those 
Nef induced genes prevented from induction in the absence of TCRÇ and ZAP- 
70). An 89% overlap was observed between genes repressed in the absence of 
TCR^ and those repressed in the absence of ZAP-70. The Nef TCR^ interaction 
may contribute to Nef virulence enhancement as several genes associated with 
increased viral productivity are not induced in its absence including c-myb, 
NFATc, IRF2, CDK9, TAT SF1, TRBP, U1 SNRNP and c-abl. Therefore 
formation of the complete Nef transcriptional program requires TCR^ and ZAP- 
70. In addition it is initiated at the highest level in the T cell signalling path.
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Fig 4g. Nef tet inauciDle cell lines were create J in p 116 and RT3-T3.5 J jtk a t  
ceil m es by co-transtecting eacn cell line with plasmids cancaming the tet 
t"ansactivatcr element, the tet operator sequence and nef bicistrcnic with 
EG FP anc a hygromycin resistance casette W estern piiOts 'Of Nef expression 
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Cell line p i 16 IS qenehcaily deficient in ZA P-70 and R T3-T3.5  contains 
function ally deficient TCP'C.
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Figure 41. Ordered lists showing genes inhibited in induction in the 
absence of functional TCR^ or ZAP-70 and genes unaffected after Nef 
expression. Gene inhibition is defined by normalised relative 
expression ratio reduced by more than 30% of the value obtained after 
Nef expression in Jurkat at 36 hours. This data is obtained from array 
HG 1.2 III but is representative of data obtained from all three arrays 
studied. A full list of genes inhibited in induction in each condition is 
supplied in the appendix. The colour key indicates upregulated genes 
as saturated red.
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4.6 Contribution of the SH3 binding domain to transcriptional programme
The domain of Nef that has most commonly been implicated in binding to host T 
cell signalling moieties is the SH3 binding domain. To explore the contribution of 
this domain to the Nef gene expression profile a tetracycline inducible cell line 
using the mutant Nef construct P76A was created. Western blot and FACS 
analysis of gene induction of this mutant in Jurkat is demonstrated (Figure 4j). 
Many single cell clones must be screened before identification of a clone 
exhibiting reasonable gene induction with minimal background leak. Most clones 
screened show no evidence of EGFP expression (Figure 4.11). Cells were 
induced and RNA prepared for cDNA microarray analysis. Examination of the 
P76A expression profile demonstrated 59% of WT Nef induced genes were not 
detected (Figure 4k and Figure 41). This is the most marked attenuation of the 
expression profile of all the conditions tested. However the failure to repress 
100% of the induced genes indicates other domains apart from the SH3 binding 
domain must be involved in generating expression changes. HIV related genes 
induced by WT Nef but failing to be expressed by P76A are listed in red in Table 
4.2. Among them are several factors that positively regulate viral replication.
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Figure 4j. A P76A Nef tet inducble cell line was generated and 
expression tested by western blot after induction witti doxycycline. Many 
clones are screened to identify a clone with reasonable Nef expression 
and minimal background leak. The bottom panel shows FACS analysis of 
EGFP expression after doxycycline treatment in two single cell clones. 
Most clones screened demonstrate no EGFP expression as shown for 
clone 113.056 in the middle panel. SuccessfU EGFP induction was 
observed for clone 11.073.
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Figure 4k. Scatter plots 
demonstraling removal of the 
Nef SH3 binding domain 
suppresses a large amount of 
differential gene expression 
occuring after expression of WT 
Nef in T cells. Raw intensity 
values are plotted against 
control values for each gene. 
The green lines indicate the 
relative expressicn of the data 
sets relativeto time 0. The upper 
line marks a two-fold inciease, 
the lower line marks a two-fold 
decrease and the centre line 
indicates equivalent expression. 
The colour scale indicates 
relative up and downregulation 
o f genes with red representing 
up and purple downregulation.
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Figure 41. Ordered list representation of WT Nef induced genes in comparison 
with P76A induced genes. The colour key indicates upregulated genes as 
saturated red. In total removing the Nef SH3 binding domain removes 59% Nef 
induced genes. P76A Nef exclusively induces some genes not upregulated by 
WT Nef. This ordered list is generated from data obtained from array HG 1.2 III. 
It is representative of results obtained from all three arrays.
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4.7 Summary
It has been possible to compare reference activation states to the Nef expression 
profile and demonstrate a close identity to a reference T cell activation state. The 
strength of using Jurkat T cells as a model system derives from the fact that this 
cell line has been used to delineate many aspects of T cell signalling. In addition 
several genetically null and functionally deficient mutants are available that 
enable a dissection of a mechanism for Nef signalling. Evidence obtained from 
the different conditions examined demonstrates Nef acts at the highest level in 
the T cell signalling path. In addition the SH3 binding domain of Nef is involved in 
generation of the gene expression profile.
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Chapters 
Proteomic Analysis of Nef in T Cells
5.1 introduction
The Nef gene expression profile suggests Nef may exert a specific effect on T 
cell transcriptional activity. In addition it indicates that Nef activates T cell 
signalling cascades at a point proximal to TCR^-associated ZAP-70. As 
discussed previously it is unlikely that Nef acts via a single protein-protein 
interaction to induce these effects but likely as part of a multi-component 
complex. In support of this there is no described structural basis by which a motif 
in Nef could facilitate phosphorylation of tyrosine residues in the cytoplasmic tail 
of TCR^ without participation of a third party.
T cell activation requires sustained T cell receptor interaction with MHC-peptide 
complexes in the immunological synapse formed between the T cell and antigen 
presenting cell (ARC). A synaptic basis for immune cell interaction was 
suggested in 1984 after the identification of T cells, APCs, lymphocyte cell 
adhesion molecules and the TCR (Norcross, 1984). Subsequently many T cell- 
APC interactions have fulfilled parameters equating with neurological synapse 
behaviour. These include the fact T cells and APCs remain discrete cells during 
the interaction (Unanue, 1984) and the fact adhesion molecules link the two cell 
types together (Springer, 1990). In addition vectorial secretion is a property of 
immune cell interaction (Paula and Seder, 1994 and the TCR:MHCp interaction 
delivers a stop signal to ensure positional stability (Dustin et al., 1997).
The immunological synapse is composed of SMACs (supramolecular activation 
clusters (Dustin et al., 1998). The central or cSMAC is composed of a central 
cluster of TCR:MHCp interactions surrounded by a ring of LFA-T.ICAM-1 integrin 
mediated interactions (peripheral or pSMAC) (Monks et al., 1998). The Golgi and
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microtubule organising centre are positioned within a micrometer of the cSMAC 
and radiating microtubules contact the pSMAC (Kupfer et al., 1994). Mature 
synapse formation takes minutes but may be stable for hours (Grakoui, 1999). 
SMACs contain several signalling components. These include Src and Syk family 
kinases, PKC0 and Cdc42-GTP (Bromley et al., 2001). The immunological 
synapse also contains adaptor proteins such as SLP-76, Fyb and Nek that are 
linked directly or indirectly to proteins such as WASP, EnaA/ASP family members 
that are involved in actin polymerisation (Krause et al., 2000; Monks et al., 1998). 
Interaction between the T cell receptor (TCR) and peptide loaded major 
histocompatibility complex (MHC) molecules on the surface of the ARC induces 
the formation of clusters at the contact site that are enriched in filamentous actin 
(F-actin) (Grakoui et al., 1999; Penninger and Crabtree, 1999). The 
accumulation of F-actin at the T cell APC interface is thought to stabilise a 
connection between T cells and APCs that is continuous and required for optimal 
T cell activation. Inhibition of F-actin polymerization by cytochalasin blocks 
synapse formation and T cell activation (Wulfing and Davis, 1998).
The earliest step in formation of the immunological synapse can be correlated 
with topologically based receptor segregation based on the size of different 
receptor ligand pairs (Springer 1990). Evidence for this has been obtained by 
using CD48 artificially lengthened to contain several additional domains. Here 
CD2:CD48 pairs inhibited efficient TCR activation by the APC (Wild et al., 1999). 
The driving force for this segregation might be the thermodynamic advantage of 
aligning membrane surfaces with nm precision that serves to enhance 
interactions (Dustin et al., 1997).
How the SMAC becomes organised is not clear. Several hypotheses have 
arisen. There is some evidence to suggest that direct actin-myosin based 
transport toward the synapse is active during synapse formation (Wulfing and 
Davis., 1998). An alternative suggestion is based on the coupling between 
thermally driven membrane fluctuations and the kinetics and mechanisms of the 
different types of receptor-ligand interactions (Qi et al., 2001). This model has 
been named the synapse assembly model. When the membrane oscillations
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harmonize with kinetics of receptor-ligand interactions patterns like the 
immunological synapse can be generated by computer simulation. This model 
predicts that some self-MHCps may synergise with agonist MHCp to lower the 
threshold for mature synapse formation (Lee et al., 2002/3). Recently 
experimental evidence in support of this prediction has been derived (Wulfing et 
al., 2002).
Nef can localise to lipid rafts in T cells (Wang et al., 2000, Schrager et al., 1999). 
It is possible Nef forms a signalosome within rafts to facilitate signalling. Lipid 
rafts appear to play essential roles in signalling initiated through TCRs (Xavier et 
al., 1998), BCRs (Cheng et al., 2001) and several Fc-receptors (Field et al., 
1995). These receptors are in their resting state devoid of any associated protein 
tyrosine kinases. Then upon cross linking their aggregates merge with 
membrane rafts and immune-receptor based tyrosine activation motifs (ITAMS) 
present in the cytoplasmic tails of their signalling chains become exposed to Src 
kinases in rafts (Harder, 2001). Several other components of the early phase of 
signalling such as PIP2 and LAT also constitutively reside in rafts. TCRs may be 
pre-associated with membrane rafts and their crosslinking may reorganise this 
assembly to allow for optimal CD3 exposure to Src family kinases. Support for 
this comes from several lines of evidence.
Constitutive association of the pre-TCR with lipid rafts is sufficient for eliciting 
signals required for pre-thymocyte survival (Foti et al., 2002). Partial raft 
dispersal by cholesterol depletion inhibits early TCR-triggered events such as 
tyrosine phosphorylation of TCRÇ and calcium flux (Stulnig et al., 1998/ 
Membrane rafts are also partially disrupted in T cells exposed to corticosteroid 
correlating with defective TCR signalling (Van Laethem et al., 2001). T cells from 
acid shingomyelase knockout mice which are deficient in membrane rafts due to 
decreased cholesterol content have defects in TCR induced tyrosine 
phosphorylation and T cell proliferation (Nix et al., 2000). Wild-type Lck and LAT 
molecules capable of targeting to rafts but not their membrane associated raft 
non-targeted mutants are able to reconstitute TCR signalling defects in 
appropriate mutant T cell lines (Kabouridis et al., 1997). In addition artificial
targeting of other cytoplasmic molecules such as SHP-1 (Veri et al., 2001), CD45 
(He et al., 2002) or PLCy (Melkonian et al., 1999) to membrane rafts results in 
marked functional effects on TCR induced signalling. Finally mutation of the 
TCR connecting peptide that interferes with increased ^ chain raft association in 
response to partial agonist antigen affects Erk activation and thymocyte positive 
selection (Werlen et al., 2000). Similar signalling defects are observed in T cells 
of CD3Ô knockout mice where the TCR/CD3 complex is deficient in membrane 
raft association (Delgado et al., 2000).
The manner by which rafts coordinate T cell signalling is poorly understood. 
Major subsets of CD4 and CD8 are located in rafts (Parolini et al., 1996) as is 
Fyn (Stuemer et al., 2001). It is not clear whether sequestration in membrane 
rafts helps keep Src family kinases in an active or inactive state. CD45 is a major 
positive regulator of these kinases however it is sequestered away from rafts. In 
contrast a fraction of the negative regulator Csk is a raft component. Activation 
induced association of TCRs with membrane rafts seems to be dependant on an 
extracellular proteoglycan agrin, previously known to aggregate receptors at the 
neuromuscular junction. A T cell specific form of agrin has been shown can 
aggregate lipid rafts and enhance T cell activation induced by either CD3 
crosslinking or by peptide antigen (Khan et al., 2001). It is possible agrin 
functions like antibodies to GPI-anchored proteins present in rafts although the 
ligand has not so far been demonstrated. Membrane rafts also play an important 
role in the process of co-stimulation. CD28 mediated co-stimulation is 
accompanied by a major raft redistribution from intracellular reservoirs to the cell 
surface (Viola et al., 1999). This appears to be regulated by a cytoskeletal 
dependant mechanism that is poorly understood.
TCR interactions with membrane rafts have been correlated with actin 
cytoskeletal rearrangements on T cell activation. Lipid raft polarisation in the 
immunological synapse depends on various signalling proteins including Vav-1, 
Rac and WASP (Villalba et al., 2001). Another molecular complex playing roles in 
these raft membrane rearrangements include Slp-76, Nek, Fyn, PAK and PKC0. 
The activated TCR complex crosslinks to the actin cytoskeleton through the
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tyrosine phosphorylated Çchain and this interaction is enhanced when 
aggregated TCRs associate in lipid rafts (Kosugi et al., 1999). Association of 
lipid rafts with cytoskeleton may be mediated through some of the proteins 
residing in rafts such as the PAG/Cbp connected to F-actin through EPB50 and 
ezrin/radixin/moesin (Torgersen et al., 2001) or the adhesion protein CD44. The 
phospholipid PIP2 is also involved in recruitment of the WASP protein to be 
aggregated to membrane rafts where it functions in actin nucléation through 
associated Arp2/3 complex (Rozelle etal., 2000). Accumulation of F-actin under 
patches of aggregated rafts correlates with presence of tyrosine phosphorylated 
proteins (Harder et al., 1999). It is not known whether reorganisation of actin 
cytoskeleton is required for raft clustering or whether raft clustering promotes 
polymerisation of the actin cytoskeleton. Interestingly Nef has been shown to 
facilitate actin polymerisation in 293 cells with resultant induction of lamellipodia 
in a Vav/Cdc42 dependant interaction (Fackler et al., 1999).
Previous attempts to define a signalling module by which Nef acts have utilised 
information gleaned from structural studies and from in vitro pull down assays. 
Nef is promiscuous in binding in vitro and thus many described interactions may 
have little relevance in vivo. The yeast-2-hybrid system was previously used to 
probe Nef protein-protein interactions. This system can probe millions of 
interactions and is therefore suitable for large scale screening of protein-protein 
interactions however in general this in vivo system cannot readily detect 
interactions with multiple components or interactions occurring under particular 
environmental conditions eg. (Ca^ concentration and co-factors such as low 
molecular weight metabolite and post-translational modifications ie. 
phosphorylation, glycosylation, acrylation and alkylation). As activation of a 
signalling cascade by Nef is likely to involve an interaction dependant on 
changes in phosphorylation the yeast-2-hybrid is unlikely to identify such a 
complex.
Proteomics using 2D gel analysis followed by mass spectrometry was 
undertaken to attempt to define a signalling complex by which Nef might relay 
specific information to the T cell nucleus. Figure 5a illustrates the steps involved.
Figure 5a Flow diagram illustrating steps involved in proteomic analysis 
investigating Nef mediated signalling in T cells.
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Protein samples were run on 2D gels using pH 3-10 linear IPG strips from 
Amersham and subsequently electrophoresed on 12.5% precast SDS gels. Gels 
were analysed using a software (Melanie 3.0) normalising and aligning gel 
images after silver staining. Automated spot picking resulted in generation of a 
number of gel fragments that were digested (Figure 5b) and analysed by mass 
spectrometry or peptide microsequencing. While this approach appears 
reasonable in attempting to delineate a complete functional Nef signalling module 
it is worth noting 2D gel analysis is currently seriously limited with regard to 
detection of very basic or acidic proteins, those with very large or small molecular 
weights and in detection of proteins present in very low abundance. In addition it 
is notoriously difficult to separate proteins embedded in cell membranes using 
this methodology.
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Figure 5b. Method for in gel digestion of protein samples prior to mass 
spectrometry.
Manual digest 
(general. fi-Ofn holqerp
Dry gel pieces in speedvac (1 -2  hrs)
Wash;
3 times
Add 50 jjil of 20 mM NKtHCOj in water -  Shake for 20 min at room  tanperature - 
Remove supernatant 
Reduction with DTT:
Add 10 mM DTT in 20 mM NH4 HCO3 in water (volum e should cover gel piece) -
shake for 4 5  min at room tem perature -  Remove supernatant____________  '
Alkylation with lodoacetamide:
Add 50 mM lodoacetamide in 20 mM NHtHCOj in w ater (volum e should cover gel
piece) -  shake for 20 min at room tem perature in dark -  Remove supernatant_____
Wash: 3 times
Add 5 0 j i l  of 20 mM NI-UHCOj in 50%  acetonitrile -  Shake for 20 min at room  
tem perature -  
Remove supernatant
Add 50 pi of 100%  acetonitrile -  Shake for 20 min dt room tennperature -
Remove supernatant
Dry gel pieces in speedvac (Ih)
Note: gel pieces turn white_______________________________________________________
Trypsin (sequence grade):
Add 10 p i (volum e may be increased based on size of gel piece) of 10 ng/pl 
trypsin solution in 20 mM NH4 HCO3 in water -  After 5 min, remcwe excess trypsin 
solution and add 1 0 pi of 20 mM NH4 HCO3 in water -  Incubate over night at 37* C 
(1 2 -1 5  hrs).
Note: modified trypsin may be used to  minimize autolysis products.
Prepare trypsin digest solution from  original stock solution ju s t before use 
Extraction o f peptides:
3 tim es with 50 p i of 5%  formic acid in 50%  acetonitrile -  20 min shake -  Collect 
and pool supernatants in new vials (discard gel pieces)
Dry peptide extracts in speedvac_______________________________________________
Reconstitution:
Dissolve in 0 .1%  TFA (MALDI) or 0 .1%  FA (E S I) in H iO  (6 -1 0  p i) by vortex for 3 
s -  shake for 2 0  min -  sonicate for 2  rrin
5.2 Nef interacting proteins in lipid rafts
In order to perform an analysis of Nef interacting proteins in rafts it was 
necessary to immunoprecipitate Nef without disrupting any potential interaction. 
C-terminal HA tagged Nef was created by including the haemaglutinin (HA) 
sequence in a PCR primer and cloning WT-HA Nef into plRES-2-EGFP 
expression vector. Jurkat were then transfected with this construct or a control 
empty vector. Lipid raft fractions were isolated by sucrose density gradient 
centrifugation. The presence of the raft marker GM1 and absence of the 
phosphatase CD45 was confirmed by western blotting of serial 1ml fractions 
harvested from the rafts samples (Figure 5c). Nef was immunoprecipitated from 
the raft fractions using an anti-HA antibody. The resulting immunoprecipitate was 
run on 2D gels pH gradient 3-10. Immunoprecipitates obtained with WT Nef
"inR
were compared to those obtained with the SH3 binding mutant P76A Nef. WT 
HA-tagged Nef co-immunoprecipitates specifically with several proteins in this 
context (Figure 5d). The identity of these is being investigated at present.
Figure 5c. Lipid rafts were purified by sucrose density gradient centrifugation. 
Western blot confirms fractions 2 and 3 contain rafts as GM1 is present and 
CD45 excluded.
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Figure 5d. 2D gel analysis of WT Nef and P76A Nef immunoprecipitated from 
raft fractions.
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5.3 Raft proteome in the presence and absence of HIV Nef
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Activation of T lymphocytes is initiated by interaction of clonally distributed 
antigen receptors with peptide-MHC ligands on the surface of antigen presenting 
cells. Signalling resulting from these recognition events is initiated in seconds 
and persists for hours. Surrounding the TCR and peptide MHC are multiple co­
receptors and counter-receptors that influence the signalling event. The 
molecular basis of signal initiation and integration via co-receptors is not 
understood. Recently the mechanism of signal initiation after TCR stimulation 
has begun to be explored in the context of cell biology. Membrane sub-domains 
known as DIGs, GEMs or lipid rafts are lipid fractions insoluble in low 
concentrations of non-ionic detergents at 4°C. A significant fraction of acylated 
and glycosyl-phosphadoidylinositol linked proteins are concentrated in lipid rafts. 
Upon TCR engagement translocation of non-lipid modified signal transduction 
molecules are drawn towards the raft fraction. Difficulties in standardisation 
between experiments have occurred and controversy exists how much TCR is 
translocated to the lipid raft fraction after antigen receptor engagement. Some 
have claimed that only a significant fraction of the phosphorylated ^ chain but not 
a/p dimer is present. Translocation of various signalling components represents 
an ideal way of compartmentalisation of signalling modules and bringing them 
into proximity with their substrates.
Analysis of the role of lipid rafts in generation and propagation of signals is 
unclear. It has been shown stimulation through the TCR increases raft 
expression, One group has shown that co-stimulation via CD28 results in raft 
aggregation that might lead to more efficient signalling by bringing more 
signalling components into proximity. Lipid raft reorganisation is not sufficient for 
co-stimulation simply aggregating rafts by applying cholera toxin does not 
facilitate signalling. Rafts also provide a link between the TCR and the 
cytoskeleton (Penninger et al., 1999). Association of the TCR^ with the 
cytoskeleton after receptor engagement is dependant on lipid raft integrity.
The protein complement of CD4 T cell lipid rafts in the presence and absence of 
Nef was explored. Current mass spectrometry methods for elucidating 
membrane proteins involve either gel based methods or “shotgun” methods in
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which complex protein mixtures are proteolytically digested before separation 
and analysis by LC/MS approaches. The limitation of the gel based approach for 
membrane proteins remains solubility. Many hydrophobic proteins are not 
solubilised in the non-detergent isoelectric focusing sample buffer. In addition 
solubilised proteins are prone to precipitation at their isoelectric point. Limited 
dynamic range of detection is also an issue because membrane proteins are 
typically lower in abundance when compared with soluble proteins. However 
subcellular fractionation and directed biochemical enrichments can overcome 
many of these issues. In addition improved solubilization of membrane fractions 
can be achieved by treatment with organic solvents or non-ionic or zwitterionic 
detergents before gel analysis. In this analysis lipid rafts were obtained after 
sucrose density gradient centifugation. Samples then underwent dialysis to 
remove sucrose. During this procedure it was noted a high proportion of protein 
was lost. 400^g protein was loaded for each 2D gel run. Differences were noted 
between Nef expressing and nonexpressing raft fractions (Figure 5e). New 
proteins were recruited to rafts in the presence of Nef and their identity is 
currently being established by mass spectrometry.
inft
Figure 5e. Changes in lipid raft protein content in control and Nef expressing 
Jurkat CD4 T cells. Lipid rafts were run on pH 3-10 linear IPG strips and 12.5% 
precast SDS gels. Figures 5c (i), (ii), (iii) and (iv) represent gels obtained with 
control samples and Figures 5c (v), (vi), (vii) and (viii) are gels obtained after Nef 
expression.
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5.4 Use of sIRNA to establish which Nef interacting proteins functionally 
contribute to Nef T cell activation
Use of siRNA to inhibit protein expression enables functional characterisation of 
individual genes in specific contexts. The mechanism of siRNA action in 
facilitating degradation of cognate mRNA is illustrated in Figure 5f.
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Figure 5f. Schematic representing the known stages of degradation of mRNA 
after endogenous dsRNA formation in mammalian cells. The diagram shows how 
synthetic siRNAs introduced by transfection or produced from a vector feed into 
the RISC complex.
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In order to identify which Nef interactors identified by mass spectrometry 
contribute to Nef mediated T cell signalling a screening system was constructed 
using siRNA expression vectors. As several proteins are likely to be involved 
using gene expression profiling as a readout is time consuming and expensive. 
Nef has previously been demonstrated to induce actin polymerisation in T cells 
via an interaction with Vav and Cdc42 (Fackler et al., 1999) (Figure 5g).
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Figure 5g. Confocal image of Nef transfected cells stained for filamentous actin 
using phalloidin oregan green.
The assay for functional contribution of proteins identified by mass spectrometry 
measures actin polymerisation as a read-out. Co-transfection of Jurkat with Nef 
and a siRNA vector corresponding to the gene of interest and documentation of 
actin polymerisation observed by confocal microscopy is being used to assess 
which proteins functionally contribute to Nef mediated T cell activation.
5.5 Design of siRNA expression vectors
siRNA expression vectors were designed. The U6 RNA polymerase III promoter 
was used. This promoter has been shown to successfully direct expression of 21 
nt siRNAs in mammalian cells. U6 promoter directs expression of snRNAs 
physiologically and transcripts are processed to contain terminal TT. This TT 
signal is recognised by the RISC complex that facilitates degradation of cognate 
mRNA. Oligonucleotides corresponding to sequence from EGFP were annealed 
by heating at 100°C for 5 minutes and then cooling on the bench. These were 
ligated to Apal/ EcoRI cloning sites in pBS-U6. An additional vector was 
designed to act as an siRNA reporter vector and to direct expression of nef 
simultaneously. The bi-directional rtTA Tet vector pBI from Clontech was used. 
IRES-EGFP was subcloned from plRES-2-EGFP at PstI/ Notl in MGS 1. The U6 
was shuttled from pBS-U6 at Xhol after a Xhol linker was placed at Pst I. The 
second MGS was used to express nef.
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The functional contribution to Nef mediated signalling of proteins identified by 
mass spectrometry is being assessed. First the proteins are being knocked down 
in Jurkat by transfection of siRNA expression vectors. The ability of these vectors 
to inhibit proteins expression is being determined using western blot, confocal 
analysis or FACS analysis. In the case of western blot this is less than ideal for 
Jurkat as invariably a maximal transfection efficiency of 30-40% only is obtained 
after transient transfection. Therefore it is hard to quantitate the effect of a 
particular vector as shown in Figure 5f. Here a siRNA vector directed against 
l_AT has been transfected in Jurkat and protein level of LAT assessed by western 
blot after 48 hours. The changes are unconvincing. Confocal enables direct 
assessment of transfected cells by analysis of EGFP and staining for the protein 
of interest.
Figure 5f. Western blot of LAT expression in Jurkat after transfection of a control 
and anti-LAT siRNA vector.
JT+ JT+
pBS pBS-siRNA-LAT
WB LAT 
WB actin
5.6 The Nef Proteome in T cells
Microarray analysis suggests Nef generates a transcriptional programme in T 
cells that mimics the gene expression profile obtained after Jurkat CD4 T cells 
are cross-linked with anti-CD3. These findings point to role of Nef in regulating 
some of the earliest stages of the viral life cycle. This is intriguing given the 
recent evidence that nef transcripts are produced prior to integration of the virus
into the genome of resting T cells, resulting in accumulation of Nef protein that 
primes viral synthesis upon T cell activation (Wu and Marsh., 2001). 
Transcriptional changes do not necessarily reflect changes in protein synthesis. 
Indeed it has been noted that changes in level of mRNA species often correlates 
poorly with changes in respective protein expression.
A proteomic analysis of Jurkat CD4 T cells was performed after expression of 
Nef in these cells. At 24 hours post Nef expression 50 x 10® cells were lysed with 
NP40 lysis buffer. Results of 2D gel analysis of control and Nef positive lysates
Figure 5.c 2D gel analysis of Jurkat whole cell lysates in the absence (i, ii, iii, iv) 
and presence of Nef (v, vi, vii, viii). 500^g protein was used for each gel. 24 cm 
linear IPG strips were used together with pre-cast 12.5% SDS gels. Gels were 
silver stained prior to Melanie analysis.
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are shown in figure 5c. The experiment was imperfect for several reasons. Firstly 
it was not possible to utilise the tetracycline inducible system in this instance. To
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perform each experiment large quantities of cells were required to generate 
enough protein for each 2D gel. Due to leakiness and loss of expression in the 
tet system it is difficult to generate the quantités of Nef expressing cells required 
in a short time period. However the purpose of carrying out a proteomic analysis 
was not simply one of annotating a possible Nef effect but to generate leads that 
could be followed and individually substantiated. Expression data invariably falls 
short in this regard as often changes in gene expression are not indicative of 
changes in gene function. Samples used were Jurkat transiently transfected with 
Nef expression vectors. In each instance 35-40% transfection efficiency was 
achieved with either Nef or control vectors. Analysis of results therefore must 
take into account the fact changes in protein levels might reflect changes 
occuring directly in Nef expessing cells or in bystander cells as a secondary 
phenomenon.
Another shortfall of this experiment was the methodology utiltised for 2D gel 
analysis. The ideal method for use in this experiment would be to use differential 
in gel electrophoresis. Proteins from one sample are tagged with a single 
fluorescent compound, while those from another sample are tagged with a 
different fluorescent dye. The two samples are then mixed together and the 
individual proteins are separated on a single 2D gel. This enables clear analysis 
of differentially regulated proteins. In addition 2D gels analysis is currently 
seriously limited with regard to detection of very basic or acidic proteins, those 
with very large or small molecular weights and in detection of proteins present in 
very low abundance. In addition it is notoriously difficult to separate proteins 
embedded in cell membranes.
The 2D gel results indicate that Nef generates gene expression changes in T 
cells that result in induction of a specific Nef T cell proteome. The identity of 
these proteins is being elucidated using mass spectrometry. The nature of the 
proteins differentially expressed in whole cell lysates by Nef and post- 
translational modifications produced may give clues as its role in viral 
pathogenesis
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5.7 Summary
With 30,000 to 40,000 genes potentially expressed in the human genome cells 
face the task of assembling these gene products into functional complexes and 
localising them to appropriate sites. Estimates of the number of proteins encoded 
by the human genome have varied between 200,000 and 2 million. One of the 
strategies employed to tackle this problem is to spatially restrict proteins to their 
site of function. In particular the targeting of proteins to membranes has proved 
to be an effective means of obtaining fidelity and organisation of protein-protein 
interaction modules. Nef is found expressed throughout the T cell but is 
concentrated in several subcellular compartments in particular the plasma and 
nuclear membrane. It is likely to function differently in each. In order to elucidate 
a mechanism by which Nef mediates T cell signalling Nef and interacting 
partners were extracted from lipid rafts in the T cell plasma membrane. T cell 
signalling is initiated from lipid rafts after recognition of antigen on the surface of 
antigen presenting cells. This revealed association of Nef with several interacting 
partners in an SH3 domain dependant manner under the experimental conditions 
specified. Nef also changes the composition of lipid rafts. The identity of 
interactors and differentially distributed raft proteins detected by 2D gel analysis 
is being established using mass spectrometry and peptide microsequencing.
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Chapter 6
Conclusions and Discussion
6.1 Nef transcriptional program
A central goal of the gene expression study was the identification of 
physiologically relevant targets of the Nef transduction pathway. In this way many 
of the genes induced by Nef provide pointers for unravelling individual virulence 
mechanisms. HIV-1 proviral gene expression is tightly regulated by binding of 
host cell proteins to a variety of cis acting DNA sequences located within the 
LTR. Nef induced expression of fifteen transcription factors capable of positively 
regulating the viral LTR. Seven of these are inducibly expressed on T cell 
activation. T cell inducible transcription factors demonstrate a threshold level of 
activity that is concentration dependant (Fiering et al., 1990). The subversion of 
the T cell activation path to induce these genes is likely to represent an important 
mechanism facilitating increased virion production. Expression profiling allows 
formation of new hypotheses regarding the function of Nef. Induction of Tat 
interacting proteins suggests a role for Nef in the indirect regulation of the activity 
of other HIV accessory genes. Tat is expressed at relatively low levels in HIV 
infected cells and requires the presence of additional factors to effectively direct 
processive transcription. Upregulation of CDK9 is important as failure of 
transcriptional elongation occurs in its absence (Mancebo et al., 1997; Zhu et al., 
1997). It is conceivable that among the other genes differentially regulated by Nef 
there may be some that have as yet un-described effects on the viral life cycle.
6.2 Specificity of The Nef gene expression profile
In the present study a characterisation of Nef mediated T cell signalling has been 
undertaken in terms of the resulting transcriptional response. Comparison of the
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Nef expression profile with that obtained after T cell activation through CDS has 
revealed strong identity but also a small number of important differences. The 
mode of Nef T cell activation may allow a replicative advantage to the virus over 
and above a conventional activation stimulus. It was notable that within 
upregulated transcripts particular to either the Nef or anti-CD3 activation profile 
there was a relative over-representation of genes that influence HIV replication. 
This begs the question of how a viral gene might achieve specificity in signalling. 
In order to produce gene expression changes akin to those observed after anti- 
CD3 triggering it is likely similar signal transduction cascades will be activated. 
How specific signal transduction pathways relay information to the nucleus and 
dictate specific gene expression is unclear. The idea that signal transduction 
processes convey detailed amounts of information has recently been debated 
with respect to receptor tyrosine kinases (RTK).
Upon binding to their cognate ligand receptor tyrosine kinases undergo 
dimérisation and autophosphorylation on specific tyrosine residues. These 
phosphotyrosines and their adjacent sequences recruit neighbouring molecules 
via SH2 domains causing their subsequent activation. The specific activation of 
one type of RTK therefore leads to the generation of a signalling cascade. It has 
been suggested each pathway would serve a distinct function but recent gene 
profiling studies have provided evidence against this.
Fambrough et al have documented gene expression profiles obtained after 
ligation of Platelet Derived Growth Factor (PDGF) RTK. The profiles showed that 
downstream pathways were redundant in terms of what genes they activate. NIH 
3T3 cells were transfected with constructs encoding the hybrid receptors with an 
intracellular domain from the PDGFRp and extracellular domain from the M-CSF 
receptor. The chimeras contained mutations in the SH2 binding sites in the 
PDGFRp receptor. Simultaneous mutations in 5 SH2 binding sites had very little 
quantitative effect on immediate early gene induction in response to the 
heterologous ligand M-CSF. In addition mutations in any single one of these 
binding sites resulted in broad overlap in immediate early gene induction after M- 
CSF stimulation. Each site has been shown to bind PI-3K, Ras-GAP, SHP-2, and
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PLCy respectively. Thus the expression data suggest that signalling pathways 
may be functionally redundant and leave open the question of how specificity is 
achieved. Two caveats of this study are that saturating levels of ligand and 
overexpressed receptor were used in the experimental system under 
examination. These caveats can be avoided in animal models where ligands and 
receptors are expressed at physiological levels in correct temporal and tissue 
contexts. Studies in engineered mice have demonstrated that the SH2 docking 
sites in PDGFR cytoplasmic tail are not functionally redundant. Knockins of 
PDGFRp containing a mutation in the PI-3K docking site show a defect in 
interstitial fluid homeostasis and double mutants in PI-3K and PLCy SH2 binding 
sites show a defect in vascular fitness.
Other model genetic systems employed to address this question include 
Drosophila and C.elegans. Drosophila studies support the evidence obtained in 
mice that distinct molecules bound to distinct RTKs have specific functions. An 
example is a study of effects of mutations in drosophila DSHC (a homolog of 
mammalian SHC adaptor). Dshc mutants are defective in signalling from Torso 
and EGF RTKs but not from sevenless RTK demonstrating it functions within a 
receptor complex (Luschnig et al., 2000). Genetic analysis implied DSHC acts in 
parallel with other signalling proteins thought to be activated by Torso, however 
DSHC plays the central role; the redundancy with other signalling molecules here 
is partial. Therefore in vivo signalling pathways emerging from Torso RTK are not 
equivalent. A homozygous null dshc/dshc mutation is capable of negating the 
effects of a dominant constitutive Torso allele (Luschnig et al., 2000). If
DSHC were truly redundant with other effectors of Torso RTK this result would 
not be obtained. In this experiment it was possible the activated Torso allele 
elevates signalling to an artificially high level. Nevertheless the study is 
supportive of a distinct role for individual RTKs.
Investigation of Ras-MAP kinase pathway in C.elegans has revealed 
mechanisms by which specificity is achieved in specification of cell types in 
distinct developmental pathways. In part appropriate responses are obtained by 
tissue specific expression of distinct transcription factors which are targets of
199
common downstream targets of the Ras-MAP kinase path. So when the Ras- 
MAP kinase path is the effector the cell type provides the necessary specificity. 
Here the Ras-MAP kinase path was activated by triggering the LET-23 EGF 
receptor. This receptor has 8 YxxL motifs in its cytoplasmic tail. Four of these 
sites can activate through the Ras-MAP kinase path via the SH2-SH3 adaptor 
protein SEM-5 (Lesa and Sternberg 1997).
In the gene profiling results presented little signalling moiety redundancy is 
demonstrated as in each of the four conditions described between 40-59% of the 
induced genes were removed. In addition the specific differences in induced 
genes between the Nef activated and anti-CD3 activated expression profiles 
suggest the mechanism by which Nef relays signals to the nucleus is capable of 
achieving a high degree of specificity.
6.3 Overlap between the various conditions
Treatment of Nef expressing cells with the calcineurin inhibitor CsA prevents 
upregulation of 49% of Nef induced transcripts. Comparison of the hallmark Nef 
profile with that produced in TCRÇ and ZAP-70 deficient T cells reveals a key 
requirement for these in formation of the full Nef transcriptional response and 
place Nef as acting high in the T cell signalling path. Considerable overlap occurs 
between repressed genes after treatment with CsA or expression of Nef in TCR^ 
and ZAP-70 negative Jurkat. Of the 44% genes repressed in the Nef ZAP-70 
expression profile, 89% of these remain non induced in the Nef TCRÇ profile. 
Expression of Nef in TCRÇ negative T cells generates 56% overlap between 
genes repressed after CsA treatment. This overlap is greater in ZAP-70 negative 
cells at 61%. In T cells exposure of an SH3 binding domain in the CD3 
cytoplasmic tail after antigen receptor triggering facilitates Nek binding. 
Subsequently Src family tyrosine kinases are activated and phosphorylation of 
ITAM motifs in TCR^ cytoplasmic tail results in recruitment of ZAP-70. Our 
results provide genetic evidence for a requirement for TCRÇ and ZAP-70 in 
generation of the Nef transcriptome. Elucidating how Nef usurps the activation
path above the level of TCRÇ may provide information about the initial events 
occurring after antigen receptor triggering.
A potential limitation in interpretation of the observations of wide overlap between 
gene expression sets among the various conditions described is that 
complementation of the missing signalling molecules studied was not performed. 
It is possible that the mutant cell lines have undergone other adaptive changes 
and that the levels of Nef protein in each cell line under test were not identical. In 
addition the study was limited in usefulness as only 3528 genes were tested. 
However the evidence from gene profiling would suggest that multiple signalling 
components are involved in triggering an activation response.
6.4 Mechanism of T cell signalling triggered by Nef
The molecular interaction by which Nef generates gene expression changes is 
being determined. A proteomic analysis has revealed Nef expression is 
associated with an alteration of the protein complement of lipid rafts in T cells. 
Initial analysis has revealed Nef mediated assocation of signalling proteins and 
proteins implicated in actin polymerisation with rafts. In addition Nef appears 
associate with several proteins in lipid rafts the identity of which are currently 
being determined. Putative in vivo interactions are being confimed by co- 
immunoprecipitation, co-localisation and by knockdown of the identified protein 
using siRNAs. A series of siRNA expression vectors have been constructed to 
enable identification of transfected cells with a fluorescent reporter. Bi-directional 
vectors expressing nef and the respective siRNA oligonucleotide targeted to a 
gene of interest are transfected into Jurkat. Ability of Nef to induce actin 
polymerisation in the presence and absence of each siRNA will be assessed. 
This will provide a functional readout for the contribution of each Nef interactor in 
Nef mediated T cell signalling.
Nef possesses no intrinsic enzymatic ability and there is no known structural 
basis for its ability to associate with certain signalling proteins such as TCRÇ and 
PAK kinase. It is likely Nef acts as an adaptor in the T cell signalling path. An
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unusual feature of Nef structure is the presence of several flexible regions that is 
not common for a cytoplasmic protein. This could explain so many of the diverse 
reported interactions of Nef as the flexible regions can provide an extensive 
accessible surface. It is possible Nef may act as an alternative signalling scaffold 
enforcing proximity between divergent signalling modules that would not normally 
interact in T cells. The gene expression profile generated by Nef does not exactly 
match that of anti-CD3 triggering. The induction of genes positively regulating the 
viral life cycle exclusively by Nef is suggestive of a degree of specificity in the 
activation trigger. The exact means by which Nef subverts T cell signalling is 
being investigated. We are determining whether Nef acts as alternative signalling 
scaffold or simply replaces an exogenous activation signal. It has been 
postulated adaptors might facilitate signalling by acting as “meta-enzymes”. They 
might bind, orient, align and allosterically regulate kinases. Alternatively they may 
simply spatially regulate and facilitate signal transmission through enforced 
proximity. Evidence supportive of a role for scaffolds in enforced proximity has 
recently been gathered in yeast using the scaffold protein Ste5. This scaffold is 
critical for mating pheromone responses in budding yeast. When Ste5 is present, 
pheromone causes Fus3 to be activated and mating occurs. When Ste5 is 
absent, there is no Fus3 activation and no mating response. Ste5 binds all three 
members of the Ste11-Ste7-Fus3 MAP kinase cascade, thereby allowing them to 
be activated by their upstream regulators. Evidence for alternative signalling 
scaffolds acting to promote adaptor function has come from a study by Park et 
al., 2003. Here a new signalling pathway was created by uniting two defective 
scaffolds. The experiment relied on the fact that four distinct MAK kinase 
cascades in S.cerevisiae use the same MAPKKK, Ste11, and yet each cascade 
receives signals from distinct upstream inputs and relays them to specific 
downstream effectors, with little interfering cross-talk. Park et al linked a Ste5 
protein that could receive signals from Ste4, but relay them only as far as Ste11, 
to a Pbs2 protein defective for receiving osmotic signals from the upstream Sho1 
protein. Expression of this defective scaffold caused mating pheromone to trigger 
typical hyperosmolar responses rather then mating responses.
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The modules in which Nef acts are being compared to that occurring after T cell 
activation. We are immunoprecipitating various constituents of the Nef signalling 
module in the presence and absence of Nef and pre and post T cell activation. It 
will be established whether Nef acts as alternative connector of various signalling 
proteins producing a novel signalling path. By combining simple modular binding 
interactions in a combinatorial fashion scaffolds could generate high molecular 
complexity and impose specificity without requiring the evolution of signalling 
proteins themselves.
6.5 Role of the Nef expression profile in the viral life cycle
The Nef expression profile provides a molecular explanation for the observations 
of anti-CD3 hyper-reactivity of Nef transgenic thymocytes (Hanna et al., 1998) 
and Nef transfected T cells (Schrager and Marsh, 1999; Wang et al., 2000). This 
form of priming results in hyperinduction of T cell inducible genes after full 
exogenous activation and is likely to present a platform for heightened viral 
production. This study focused on the target genes of one Nef variant from HIV- 
1, SF2. SF2 is an example of a T tropic isolate of HIV commonly present in late 
stage disease. The mode of T cell activation and the expression profile 
generated by such a variant may be heightened compared to those from more 
indolent or M tropic counterparts. Cataloging the transcriptional signature of Nef 
variants from understanding of the contribution of this accessory gene in dictating 
viral post-integration fate.
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APPENDIX
Table 1. Genes upregulated by Nef over 24 hours
Encoded
Protein
GenBank
Accession
Number
Cluster
classification
Previous 
association 
with HIV
Previous 
association 
with T cell 
activation
LUCA2 U09577 B
ARK1 □84212 A
SAS U01160 B
LUCA 15 U23946 A
ETS-1 J04101 A yes yes
Tyro3 □17517 B
CDC2 X05360 A yes yes
CDK9 AF045161 A yes yes
BRCA2 U43746 B
ezrln X51521 A yes
BSP1 U57456 B
Jun-D X56681 A yes
c-abi M l 4752; 
Ml 4753; 
M l4754
A yes
CDK4 M14505 A yes
P16-INK4 L27211 B
P78 putative serine /threonine kinase M80359 A
ABL2 M35296 A
CDK6 X66365 B yes
DP2 U18422 A
Mdm2 Z12020;
M92424
A
Prohibitin 885655;
U17179
B
c-fos K00650 B yes yes
Ets related protein tel U11732 B
shb X75342 A
TIAM 1 U16296 B
geminin AF067855 A
c-myb M l5024 B yes
ERBB-3 M29366;
M34309
B
Diaphanous 1 AF051782 A
PTEN U92436 A
ERBB4 L07868 A
CBL-B U26710 A
Bubi AF053305 A
1F:Q
NEK2 U11050 A
CLK1 L29222 B
CDC25A M81933 A
CCK4 U 3 3 6 3 5  + 
U40271
A
ILK U40282 A
JNK1 L26318 A
GLYT-1 S70609 B
Tnk1 U43408 A
HEK M83941 B
NET M65105 B
PLC beta 3 Z16411 B
Sodium/potassium -transporting 
ATPase
D00099 B
Alpha-fetoprotein V01514 B
IL6 receptor beta subunit M57230 A
Rapamycin target protein L34075 A
BAD U66879 A
RalGDSB U14417 A
CD47 Y 0 0 8 1 5  + 
X69398
A
Adenylate cyclase type 1 L05500 A
Protein phosphatase 2B D21878 A
ATM U33841 B
Serine/threonine phosphatase 2B L14778 B
IRF1 X14454 A
Ras p21 protein activator M23379 B
Protein phosphatase 2C alpha S87759 B
DNA ligase III X84740 B
DNA-repair protein complementing 
XP-C cells
D21089 A
XRCC1 M36089 B
5-HT-3 D49394 A
DP1 L23959 B
YL-1 D43642 A
IRF2 X I5949 A
BTF2p44 Z30094 A
NF-kB p100;p52 X61498 A yes yes
GABP-alpha D13316 B yes
AREB6 D15050 B
BARD1 U76638 B
SMBP-2 L I4754 B
GLRB U33267 B
JNKK2 AF022805 B
NFATc U08015 B yes yes
NERF2 U43188 B
Cadherin 5 X79981;
X59796
B
CD106 M30257 A
H0XB7 M l6937 B
Stem cell protein M29038 B
PUR alpha M96684 B yes
EBI3 L08187 B
MIP 1-beta J04130 A yes yes
iRn
Puramycin sensitive aminopeptidase Y07701 A
Heat shock related 70kd protein 2 L26336 B yes
Glutathione peroxidase Y00483; 
M21304
B
70Kd MSP 1 M11717 B yes
TGF beta X02812;
J05114
B yes yes
MIP 1-alpha M23452 B yes yes
Estrogen sulfotransferase U08098 B
Insulin protease M21188 A
IL4 precursor M l3982 B yes yes
TALLA-1 D10653 A
IRF2 X I5949 A
PEBP2aC1 Z35278 A
H0X-D4 X04706:X17360 A
HEX L I6499 A
HIV-EP2 M60119 B yes yes
PAX-4 AB008913 B
SOX-3 X71135 B
MIZ-1 protein Y09723 A
GLI3 M57609 B
CIITA X74301 A yes yes
Insulin gene enhancer protein ISL1 U07559 B
centrin U03270 A yes
TRANCE AF013171 A
Granzyme H precursor M36118 A
Defensin alpha 1 M21130 B
NUP-98 U41815 A yes
Ectropic viral integration site protein 
2A
M55267 B
CYP1A1 and CYP1A2 K 0 3 1 9 1  +
M55053;
M38504
A
HUT2 X96969 B
Lumican precursor U18728 A
Annexin IV X05908 B
Beta'-COP X70476 B yes
SNAP-25 L I9761 A
RAB-GDI beta D13988 B
Man9-alpha-mannosidase X74837 A
Phosphofructokinase 1 D25328 A yes
Aldehyde dehydrogenase E3 
isozyme
U34252 B
PGAM J04173 B
Apo-D J02611 B
Ferritin heavy chain M97164 B yes
ALDH2 Y00109 A
Ubiquitously expressed nuclear 
receptor
U07132 A
Pregnane X receptor AF061056 A
TGF-beta 4 U81523 A yes
GDF8 AF019627 B
Natriuretic peptide precursor B M25296 B
1R1
STAM U43899 A yes
MAPKAP kinase 2 U12779 B yes
GRK4 L03718 B
PP2AB M64929 A
Dual-specificty protein phosphatase 
HVH2
U21108 A yes
Regulator of G protein signaling 6 L40394 A
Regulator of G protein signaling 16 U70426 A
PLC-delta-1 U09117 B
14-3-3 protein theta X56468 A
EBV-induced G-protein coupled 
receptor 2
L08177 A
BD73 L31785 A
Dynamin-1 L07807 A
MTBT1 J03778 B
Transmembrane protein 1 U19252 B
mucin AF007194 A yes
BST-2 D28137 A
SMCY U52191 A
Tetraspan net-5 AF089749 A
RNA pol II (RPB3) J05448 A yes
RNA pol II (RPB2) X63563 A yes
RNA polll (RPB6) Z27113 B yes
Zinc finger protein 76 M91592 A
NF-E2 related factor 2 S74017 A
Zinc finger protein 133 U09366 A
Zinc finger protein 140 U09368 A
Zinc finger protein 139 U09848 A
Zinc finger protein C2H2-25 U38904 B
Zinc finger protein 33A X68687 A
TAFII-28 X83928 B yes
Zinc finger HSAL2 X98834 A
Zinc finger (fragment) L32164 A
E74-like factor 5 AF049703 A
H-2K binding factor-2 D14041 A
EFP D21205 A
HKF-1 D76444 B
Transcription factor SL1 L39059 B
TAT-SFI U76992 A yes
HPX-42B AF068006 A
TFECL D43945 A
RNA polymerase II terminaton factor AF073771 B
RNPL U28686 A
HS-II-T1 D50495 A
mitochondrial RNA helicase AF042169 B
HA0659 X79538 B
CSTF 64KD subunit M85085 A
TRA-2 alpha U53209 A
U1 SNRNP A protein X06347 A yes
HU-antigen C L26405 B
RBP56 X98893 A
T0B4 protein D64109 B
CUL-4A U58090 B
TP beta and TP gamma U09087 B
"1A9
DEL-1 U70312 A
Microfibril associated glycoprotein 4 L38486 B
P22 phagocyte B-cytochrome M21186 B
Inositol 1,4,5-triphopshate receptor 
type 1
L38019 A yes
NK-tumour recognition protein L04288 B
FKBP25 M90309 B
SCCE L33404 A
bomapin U35459 B
mRNA encoding C4.4 like AJ223603 A
Polycomb 2 homolog AF013956 B
HSP86 X15183 B
Yolk sac permease like 3 AF058317 A
HVDAC2 L06328 B
HPCN1 M55513 B
EC3.6.1.36 U02076 B
Chloride channel protein AF026004 B
Two pore domain potassium channel AF084830 A
Ca-activated potassium channel U02632 B
Type 2 INSP3 receptor D26350 A yes
Procollagen 1 N-proteinase AJ003125 A
Collagen alpha chain 5 M31115 A
SKD1 homolog AF038960 A
Syntaxin 6 AJ002078 B
adipophilin X97324 B
NASP M97856 A
TOM 1-like protein AJ010071 A
SRP14 X73459 A
Synaptotagmin VII fragment AF038535 B
Angiogenin precursor M l1567 A
Sia alpha2,3galbeta1,4glcnAcalpha 
2,8-sialtransferase
AF004668 B
ATPase protein 9 D13119 B
Malate dehydrogenase D55654 B
Alpha-ETF J04058 B
EC 1.9.3.1 J04823 B
COX VIIA-M M83186 B
Complex I-B17 AF035840 A
CTP:phosphocholine 
cytidylyltransferase b.
AF052510 A
TPST1 AF038009 B
alpha-ketoglutarate dehydrogenase 
complex
dihydoelipoylsuccinyltransferase.
S72422 B
MTHFS L38928 B
cyclohydrolase mitochondrial  
precursor
X I6396 B
Delta-ala synthetase X56352 B
Prostatic acid phosphatase X56352 B
PAM M24902 B
glutaminyl cyclase M37721 B
spermine synthase X71125 B
Nitrilase homolog 1 Z49099 B
Carbonate dehydratase VI AF069987 B
ASF M57892 B
Acyl-CoA desaturase X97868 A
CYP-60 L77701 A
Ribophorin II U37220 A
H-SC01 Y00282 A
40s ribosomal protein 817 M l3932 A
TAR binding protein M60801 A yes
60S ribosomal protein L35A M15661 A
EF-1-beta X60656 B
P43 L38995 B
EIF-2-beta M29536 A
Statin SI X70940 B
ARGRS S80343 A
Proline tRNA ligase X54326 A
TGF beta receptor assoc protein AF022795 A
DHP1 U62647 A
ZAP-1 X99699 A
Splicing factor L10911 B
U2 small ribonucleoprotein auxilllary 
factor
D49676 B
SNRPN D49676 A
Nuclear riboprotein R AF000364 A
RNASEP protein P30 U77665 B
DIM1P homolog AF023612 B
H2A.X. X14850 B
Heat stable enterotoxin receptor L30117 B
BMP 11 AF100907 B
SNT-2 AF036718 B
Serine/threonine kinase ABO15982 A
CAMK L07044 A
SEC14-like protein U79284 B
AS-like phosphodiesterase Y08134 A
TRAP delta X90583 B
Myosin RLC J02854 B
MLC3F M20643 B
Dysferlin AF075575 B
PDZ domain containing protein AF012281 B
TRIP10 L40379 B
MP78 U29366 B
Ubiquitin conjugating enzyme E2 G1 D78514 B
Ubiquitin conjugating enzyme E2 AF031141 B
P26S4 AF031141 B
Gastrointestinal peptide AF048700 B
Motor protein D21092 B
plectin U53204 A
P60 katanin AF056022 B
MUTS homolog 4 U89293 B
TSPAN-2 AF054839 B
MYLE AF108145 A
SPOP AJ000644 A
DGS-A L77571 B
Pinch protein U09284 B
P0M-ZP3 U10099 B
1R4
KIAA0209 D86964 B
1RR
Table 2. Genes induced after CD28 activation over 24 hours
Encoded
Protein
GenBank
Accession
Number
LUCA2 U09577
SAS U01160
ETS-1 J04101
tyroS D17517
CDC2 X05360
CDK9 L25676
BRCA2 U43746
BSP1 U57456
CDK4 M14505
P16-INK4 L27211
p78 putative serine/threonine-protein kinase M80359
mdm2 protein Z12020;
M92424
c-myb M l5024
ERBB-3 M29366;
M34309
PTEN U92436
bubi AF053305
Golgi 4-transmembrane spanning transporter; MTP D14696
leukocyte surface CD47 antigen precursor Y00815 + 
X69398
adenosine A1 receptor S56143
ATM U33841
serine/threonine protein phosphatase 2B catalytic subunit alpha 
isoform
L14778
ras p21 protein activator M23379
DNA ligase III X84740
BTF2p44 Z30094
ADA2-like protein AF069732
SMBP-2 L14754
GADD45 gamma AF078078
cadherin 5 X79981;
X59796
GDI 06 M30257
PUR alpha M96684
PAH; PLANH1 X04429;
M14083
TGF-beta X02812;
J05114
estrogen sulfotransferase U08098
CD53 M37033
CD21 antigen M26004
1RR
HEX L I6499
HOMEOBOX PROTEIN EMX1 X68879
PAX-4 AB008913
MIZ-1 PROTEIN Y09723
interleukin enhancer binding factor 2 (ILF2) U58197
INSULIN GENE ENHANCER PROTEIN ISL1 U07559
centrin U03270
TRANCE AF013171
DEFENSIN, ALPHA 1 M21130
lymphocyte cytosolic protein 1 M22300
ETV1 U17163
nucleoporin NUP98 U41815
ectropic viral integration site 2A M55267
CYP1A1 + CYP1A2 K03191 +
M55053;
M38504
(CYP51) +CYP51P1 +CYP51P2 U23942 + 
U36926 + 
U40053
sodium- & chloride-dependent creatine transporter 1 (CT1) L31409
Golgi antigen gcp372 D25542
annexin IV X05908
beta'-COP X70476
SNAP-25 L I9761
ras-related protein RAB-11A X53143
RAB GDI beta D13988
glycerol kinase L I3943
ALDH7 orALDH4 U34252
apo-D J02611
nonsecretory ribonuclease precursor M28129
ubiquitously expressed nuclear receptor U07132
pregnane X receptor (PXR) AF061056
GDF8 AF019627
natriuretic peptide precursor B M25296
tyrosine-protein kinase syk L28824
MAPKAP kinase 2 U12779
dual-specificity protein phosphatase HVH2 U21108
dynamin-1 L07807
transmembrane protein 1 U19252
BST-2 D28137
SMCY. U52191
TETRASPAN NET-5. AF089749
CD39 ANTIGEN-LIKE 1 U91510
RNA POLYMERASE II (RPB7). U20659
BN51 PROTEIN. M l7754
1R7
ZINC FINGER PROTEIN 76. M91592
ZINC FINGER PROTEIN 140. U09368
ZINC FINGER PROTEIN 137. U09414
ZINC FINGER PROTEIN 139 (FRAGMENT). U09848
ZINC FINGER PROTEIN C2H2-25 U38904
ZINC FINGER PROTEIN CLONE 647 (FRAGMENT). X I6282
TRANSCRIPTION INITIATION FACTOR TFIID 28 KD SUBUNIT X83928
HKF-1. D76444
TRANSCRIPTION FACTOR SL1. L39059
HPX42B. AF068006
NASCENT POLYPEPTIDE ASSOCIATED COMPLEX ALPHA 
SUBUNIT.
X80909
HA0659 X79538
TRA-2 ALPHA U53209
HU-ANTIGEN C L26405
CUL-4A U58090
TP BETA AND TP GAMMA U09087
FKBP25 M90309
BOMAPIN U35459
POLYCOMB 2 HOMOLOG. AF013956
EC 3.6.1.36 U02076
CALCIUM-ACTIVATED POTASSIUM CHANNEL U02632
TYPE 2 INSP3 RECEPTOR D26350
PROCOLLAGEN 1 N-PROTEINASE AJ003125
COLLAGEN ALPHA 5 CHAIN PRECURSOR. M31115
ADIPOPHILIN X97324
TOM 1-LIKE PROTEIN. AJ010071
Homo sapiens putative 13 S Golgi transport complex 90kD subunit AF058718
ANGIOGENIN PRECURSOR M l1567
SIA ALPHA2.3GALBETA1,4GLCNACALPHA 2.8- 
SI ALYLTRANSFERASE
AF004668
MALATE DEHYDROGENASE D55654
UBIQUINOL-CYTOCHROME C REDUCTASE COMPLEX CORE 
PROTEIN 2 PRECURSOR
J04973
COX VIIA-M M83186
ATPASE PROTEIN 9 U09813
COMPLEX I-B17 AF035840
CTPiPHOSPHOCHOLINE CYTIDYLYLTRANSFERASE B. AF052510
TPST1 AF038009
ALPHA-KETOGLUTARATE DEHYDROGENASE COMPLEX 
DIHYDROLIPOYL SUCCINYLTRANSFERASE.
S72422
URO-D M14016
DELTA-1-PYRR0LINE-5-CARB0XYLATE DEHYDROGENASE 
PRECURSOR
U24266
MTHFS L38928
1RR
BIFUNCTIONAL METHYLENETETRAHYDROFOLATE 
DEHYDROGENASE/CYCLOHYDROLASE, MITOCHONDRIAL 
PRECURSOR
X I6396
PROSTATIC ACID PHOSPHATASE M24902
PAM M37721
SPERMINE SYNTHASE Z49099
ASF X97868
H-SC01. AF026852
ELONGATION FACTOR 1-BETA (EF-1-BETA). X60656
MULTIFUNCTIONAL AMINOACYL-TRNA SYNTHETASE 
[INCLUDES: GLUTAMYL-TRNA SYNTHETASE (EC 6.1.1.17) 
(GLUTAMATE-TRNA LIGASE); PROLYL-TRNA SYNTHETASE (EC 
6.1.1.15) (PROLINE-TRNA LIGASE)].
X54326
XIAP ASSOCIATED FACTOR-1 (ZAP-1). X99699
SPLICING FACTOR. L10911
DIM1P HOMOLOG. AF023612
HISTONE H2A.X. X14850
heat-stable enterotoxin receptor L30117
LDL RECEPTOR RELATED PROTEIN 105. AB009462
CAMK L07044
MLC3F M20643
PDZ DOMAIN CONTAINING-PROTEIN. AF012281
UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 12 U44839
UBIQUITIN-CONJUGATING ENZYME E2 G1 D78514
26S PROTEASOME SUBUNIT S5B . S79862
P26S4 L02426
GASTROINTESTINAL PEPTIDE. AFÜ4870Ü
MOTOR PROTEIN. D21092
P60 KATANIN. AF056022
MUTS HOMOLOG 4. U89293
RAD51-INTERACTING PROTEIN AF006259
1AQ
Table 3. Genes induced after GD3/CD28 stimulation of Nef expressing
cells over 24 hours
Encoded
Protein
GenBank
Accession
Number
LUCA2 U09577
ARK1 D84212
SAS U01160
LUCA 15 U23946
ETS-1 J04101
TyroS D17517
CDC2 X05360
CDK9 AF045161
BRCA2 U43746
BSP1 U57456
ezrin X51521
BSP1 U57456
Jun-D X56681
c-abI M l4752; M l4753; 
M l4754
CDK4 M l4505
P16-INK4 L27211
P78 putative serine /threonine kinase M80359
ABL2 M35296
CDK6 X66365
DP2 U18422
Mclm2 Z12020; M92424
Prohibitin S85655; U17179
c-fos K00650
Ets related protein tel U11732
shb X75342
TIAM 1 U16296
geminin AF067855
c-myb Ml 5024
ERBB-3 M29366; M34309
Diaphanous 1 AF051782
PTEN U92436
ERBB4 L07868
CBL-B U26710
Bubi AF053305
Golgi 4-transmembrane spanning transporter; MTP D14696
NEK2 U11050
CLK1 L29222
CDC25A M81933
CCK4 U33635 + U40271
ILK U40282
JNK1 L26318
GLYT-1 S70609
Tnki U43408
HEK M83941
NET M65105
PLC beta 3 Z16411
i7 n
Sodium/potassium -transporting ATPase D00099
Alpha-fetoprotein V01514
IL6 receptor beta subunit M57230
Rapamycin target protein L34075
BAD U66879
RalGDSB U14417
adenosine A1 receptor S56143
CD47 Y00815 + X69398
Adenyiate cyclase type 1 L05500
CD95 M67454
Protein phosphatase 2B D21878
ATM U33841
Serine/threonine phosphatase 2B L14778
IRF1 X I4454
Ras p21 protein activator M23379
Protein phosphatase 2C alpha S87759
DNA ligase III X84740
DNA-repair protein complementing XP-C cells D21089
XRCC1 M36089
5-HT-3 D49394
DPI L23959
YL-1 D43642
IRF2 X I5949
BTF2p44 Z30094
ADA2-like protein AF069732
NF-kB p100;p52 X61498
GABP-alpha D13316
AREB6 D15050
BARD1 U76638
SMBP-2 L14754
GADD45 gamma AF078078
GLRB U33267
JNKK2 AF022805
NFATc U08015
NERF2 U43188
Cadherin 5 X79981;X59796
CD106 M30257
IL3 precursor M l4743
112 receptor alpha precursor X01057
H0XB7 M16937
Stem cell protein M29038
PUR alpha M96684
EBI3 L08187
MIP 1-beta J04130
112 precursor A14844
Puramycin sensitive aminopeptidase Y07701
Heat shock related 70kd protein 2 L26336
Glutathione peroxidase Y00483; M21304
70Kd HSP 1 M11717
TGF beta X02812; J05114
MIP 1-alpha M23452
Estrogen sulfotransferase U08098
CD53 M37033
171
CD21 antigen M26004
Insulin protease M21188
IL4 precursor M l3982
TALLA-1 D10653
IRF2 X I5949
PEBP2aC1 Z35278
H0X-D4 X04706; X I7360
HEX L I6499
HIV-EP2 M60119
PAX-4 AB008913
SOX-3 X71135
MIZ-1 protein Y09723
GLI3 M57609
CIITA X74301
Insulin gene enhancer protein ISL1 U07559
centrin U03270
TRANCE AF013171
Granzyme H precursor M36118
Defensin alpha 1 M21130
lymphocyte cytosolic protein 1 M22300
ETV1 U17163
NUP-98 U41815
Ectropic viral integration site protein 2A M55267
CYP1A1 and CYP1A2 K03191 + M55053; 
M38504
(CYP51) +CYP51P1 +CYP51P2 U23942 + U36926 + 
U40053
sodium- & chloride-dependent creatine transporter 1 (CT1) L31409
Golgi antigen gcp372 D25542
HUT2 X96969
Lumican precursor U18728
Annexin IV X05908
Beta'-COP X70476
SNAP-25 L I9761
ras-related protein RAB-11A X53143
RAB-GDI beta D13988
Man9-alpha-mannosidase X74837
Phosphofructokinase 1 D25328
Aldehyde dehydrogenase E3 isozyme U34252
PGAM J04173
Apo-D J02611
nonsecretory ribonuclease precursor M28129
Ferritin heavy chain M97164
ALDH2 Y00109
Ubiquitously expressed nuclear receptor U07132
Pregnane X receptor AF061056
TGF-beta 4 U81523
GDF8 AF019627
Natriuretic peptide precursor B M25296
STAM U43899
MAPKAP kinase 2 U12779
tyrosine-protein kinase syk L28824
179
GRK4 L03718
PP2AB M64929
Dual-specificty protein phosphatase HVH2 U21108
Regulator of G protein signaling 6 L40394
Regulator of G protein signaling 16 U70426
PLC-delta-1 U09117
14-3-3 protein theta X56468
EBV-induced G-protein coupled receptor 2 L08177
BD73 L31785
Dynamin-1 L07807
MTBT1 J03778
Transmembrane protein 1 U19252
mucin AF007194
BST-2 D28137
SMCY U52191
Tetraspan net-5 AF089749
RNA pol II (RPB3) J05448
RNA pol II (RPB2) X63563
RNA pol II (RPB6) Z27113
RNA POLYMERASE II (RPB7). U20659
BN51 PROTEIN. M l7754
Zinc finger protein 76 M91592
NF-E2 related factor 2 S74017
Zinc finger protein 133 U09366
Zinc finger protein 140 U09368
Zinc finger protein 139 U09848
Zinc finger protein C2H2-25 U38904
Zinc finger protein 33A X68687
ZINC FINGER PROTEIN CLONE 647 (FRAGMENT). X I6282
TAFII-28 X83928
Zinc finger HSAL2 X98834
Zinc finger (fragment) L32164
E74-like factor 5 AF049703
H-2K binding factor-2 D14041
EFP D21205
HKF-1 D76444
Transcription factor SL1 L39059
TAT-SF1 U76992
HPX-42B AF068006
TFECL D43945
RNA polymerase II terminaton factor AF073771
RNPL U28686
HS-II-T1 D50495
mitochondrial RNA helicase AF042169
NASCENT POLYPEPTIDE ASSOCIATED COMPLEX ALPHA 
SUBUNIT.
X80909
HA0659 X79538
CSTF 64KD subunit M85085
TRA-2 alpha U53209
U1 SNRNP A protein X06347
HU-antigen C L26405
RBP56 X98893
T0B4 protein D64109
CUL-4A U58090
TP beta and TP gamma U09087
DEL-1 U70312
Microfibril associated glycoprotein 4 L38486
P22 phagocyte B-cytochrome M21186
Inositol 1,4,5-triphopshate receptor type 1 L38019
NK-tumour recognition protein L04288
FKBP25 M90309
SCCE L33404
bomapin U35459
mRNA encoding C4.4 like AJ223603
Polycomb 2 homolog AF013956
HSP86 X15183
Yolk sac permease like 3 AF058317
HVDAC2 L06328
HPCN1 M55513
EC3.6.1.36 U02076
Chloride channel protein AF026004
Two pore domain potassium channel AF084830
Ca-activated potassium channel U02632
Type 2 INSP3 receptor D26350
Procollagen 1 N-proteinase AJ003125
Collagen alpha chain 5 M31115
SKD1 homolog AF038960
Syntaxin 6 AJ002078
adipophilin X97324
NASP M97856
TOM 1-like protein AJ010071
SRP14 X73459
Synaptotagmin VII fragment AF038535
Homo sapiens putative 13 S Golgi transport complex 90kD subunit AF058718
Angiogenin precursor M l1567
Sia alpha2,3galbeta1,4glcnAcalpha 2,8-sialtransferase AF004668
ATPase protein 9 D13119
Malate dehydrogenase D55654
Alpha-ETF J04058
EC 1.9.3.1 J04823
UBIQUINOL-CYTOCHROME C REDUCTASE COMPLEX CORE J04973
PROTEIN 2 PRECURSOR
COX VIIA-M M83186
ATPASE PROTEIN 9 U09813
Complex I-B17 AF035840
CTP:phosphocholine cytidylyltransferase b. AF052510
TPST1 AF038009
alpha-ketoglutarate dehydrogenase 
complex dihydoelipoylsuccinyltransferase.
S72422
URO-D M14016
DELTA-1-PYRR0LINE-5-CARB0XYLATE DEHYDROGENASE U24266
PRECURSOR
MTHFS L38928
cyclohydrolase mitochondrial precursor X I6396
Delta-ala synthetase X56352
Prostatic acid phosphatase X56352
PAM M24902
glutaminyl cyclase M37721
M A
spermine synthase X71125
Nitrilase homolog 1 Z49099
Carbonate dehydratase VI AF069987
ASF M57892
Acyl-CoA desaturase X97868
CYP-60 L77701
Ribophorin II U37220
H-SC01 Y00282
40s ribosomal protein S17 M l3932
TAR binding protein M60801
60S ribosomal protein L35A M l5661
EF-1-beta X60656
P43 L38995
EIF-2-beta M29536
Statin S1 X70940
ARGRS S80343
Proline tRNA ligase X54326
TGF beta receptor assoc protein AF022795
DHP1 U62647
ZAP-1 X99699
Splicing factor L10911
U2 small ribonucleoprotein auxilllary factor D49676
SNRPN D49676
Nuclear riboprotein R AF000364
RNASEP protein P30 U77665
DIM1P homolog AF023612
H2A.X. X14850
Heat stable enterotoxin receptor L30117
BMP 11 AF100907
SNT-2 AF036718
Serine/threonine kinase ABO15982
LDL RECEPTOR RELATED PROTEIN 105. AB009462
CAMK L07044
SEC 14-like protein U79284
AS-like phosphodiesterase Y08134
TRAP delta X90583
Myosin RLC J02854
MLC3F M20643
Dysferlin AF075575
PDZ domain containing protein AF012281
TRIP10 L40379
MP78 U29366
UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 12 U44839
Ubiquitin conjugating enzyme E2 G1 D78514
Ubiquitin conjugating enzyme E2 AF031141
26S PROTEASOME SUBUNIT S5B . S79862
P26S4 AF031141
Gastrointestinal peptide AF048700
Motor protein D21092
plectin U53204
P60 katanin AF056022
MUTS homolog 4 U89293
RAD51-INTERACTING PROTEIN AF006259
17A
TSPAN-2 AF054839
MYLE AF108145
SPOP AJ000644
DGS-A L77571
Pinch protein U09284
P0M-ZP3 U10099
KIAA0209 D86964
17fi
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